

05-14-01

A

05/10/01

Jc961 U.S. PTO

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. BRA01-NP002

First Inventor BRAINARD, George

Title Photoreceptor System For Melatonin Regulation and Phototherapy

Express Mail Label No. EJ464028033US

J1036 U.S. PTO
09/853428
05/10/01

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 49]
(preferred arrangement set forth below)
- Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 12]
5. ☒ Oath or Declaration [Total Pages 1]
- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
- i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
- ii. ☐ paper
- c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☒ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other: _____

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No. _____

Prior application Information:

Examiner _____

Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 24358 (insert Customer No. or Attach bar code label here) or ☐ Correspondence address below

Name _____

Address _____

City _____ State _____ Zip Code _____

Country _____ Telephone _____ Fax _____

Name (Print/Type) Clifford Kent Weber Registration No. (Attorney/Agent) 42,215

Signature *Clifford Kent Weber* Date May 10, 2001

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

BOMBARDIER 1002
(Part 1 of 4)

05/10/01
 13961 U.S. PTO

PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 755.00)

Complete if Known

Application Number	
Filing Date	May 10, 2001
First Named Inventor	BRAINARD, George
Examiner Name	
Group Art Unit	
Attorney Docket No.	BRA01-NP002

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **50-0491**
 Deposit Account Name **Thomas Jefferson University**

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☒ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Code (\$)	Small Entity Code (\$)	Fee Description	Fee Paid
101 710	201 355	Utility filing fee	\$355.00
106 320	206 160	Design filing fee	
107 490	207 245	Plant filing fee	
108 710	208 355	Reissue filing fee	
114 150	214 75	Provisional filing fee	

SUBTOTAL (1) (\$ 355.00)

2. EXTRA CLAIM FEES

Total Claims **19** -20** = **0** x **\$9.00** = **\$0.00**
 Independent Claims **13** -3** = **10** x **\$40.00** = **\$400.00**
 Multiple Dependent **0** = **0**

Large Entity Code (\$)	Small Entity Code (\$)	Fee Description	Fee Paid
103 18	203 9	Claims in excess of 20	
102 80	202 40	Independent claims in excess of 3	
104 270	204 135	Multiple dependent claim, if not paid	
109 80	209 40	** Reissue independent claims over original patent	
110 18	210 9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$ 400.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Code	Large Entity (\$)	Small Entity (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath		
127 50	227 25	Surcharge - late provisional filing fee or cover sheet		
139 130	139 130	Non-English specification		
147 2,520	147 2,520	For filing a request for <i>ex parte</i> reexamination		
112 920*	112 920*	Requesting publication of SIR prior to Examiner action		
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action		
115 110	215 55	Extension for reply within first month		
116 390	216 195	Extension for reply within second month		
117 890	217 445	Extension for reply within third month		
118 1,390	218 695	Extension for reply within fourth month		
128 1,890	228 945	Extension for reply within fifth month		
119 310	219 155	Notice of Appeal		
120 310	220 155	Filing a brief in support of an appeal		
121 270	221 135	Request for oral hearing		
138 1,510	138 1,510	Petition to institute a public use proceeding		
140 110	240 55	Petition to revive - unavoidable		
141 1,240	241 620	Petition to revive - unintentional		
142 1,240	242 620	Utility issue fee (or reissue)		
143 440	243 220	Design issue fee		
144 600	244 300	Plant issue fee		
122 130	122 130	Petitions to the Commissioner		
123 50	123 50	Processing fee under 37 CFR 1.17(q)		
126 180	126 180	Submission of Information Disclosure Stmt		
581 40	581 40	Recording each patent assignment per property (times number of properties)		
146 710	246 355	Filing a submission after final rejection (37 CFR § 1.129(a))		
149 710	249 355	For each additional invention to be examined (37 CFR § 1.129(b))		
179 710	279 355	Request for Continued Examination (RCE)		
169 900	169 900	Request for expedited examination of a design application		

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0.00)

SUBMITTED BY

Name (Print/Type) **Clifford Kent Weber**Registration No. **42,215**
(Attorney/Agent)

Complete (if applicable)

Telephone **(215) 503-0757**

Signature _____

Date **May 10, 2001**

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DATA SHEET

DOCKET NUMBER:

BRA01-NP002

FILING TITLE:

Photoreceptor System For Melatonin Regulation And
Phototherapy

PRIORITY TO BE CLAIMED:

60/203,308 Filed May 10, 2000

APPLICANT:

THOMAS JEFFERSON UNIVERSITY
1020 Walnut Street
Philadelphia, PA 19107
United States of America

INVENTORS:

George Brainard
813 Mt. Vernon Avenue
Haddonfield, NJ 08033
USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.: BRA01-NP002

TITLE: Photoreceptor System For Melatonin Regulation And Phototherapy

INVENTOR(S): BRAINARD, George

"Express Mail" Label No. EJ464028033US
Date of Deposit – May 10, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

By Clifford Kent Weber

Typed Name: Clifford Kent Weber

Box Patent Application
Commissioner of Patents & Trademarks
Washington, DC 20231

BRA01-NP001

PATENT

**PHOTORECEPTOR SYSTEM FOR MELATONIN REGULATION AND
PHOTOTHERAPY**

5

CROSS REFERENCE TO RELATED APPLICATIONS

10 This application claims priority under 35 U.S.C. § 119 based upon U.S.
Provisional Patent Application No. 60/203,308 filed May 10, 2000 and upon U.S.
Provisional Patent Application No.60/228,493 filed August 28, 2000.

GOVERNMENT RIGHTS IN THE INVENTION

15

20 This invention was made with government support under grants from NIH
RO1NS36590 awarded by the National Institutes of Health.; NSBIR/NASA
HPF.002.08 (to GCB) awarded by the National Space Biology Research Institute in
cooperation with the National Aeronautics and Space Administration; NSF
IBN9809916 awarded by the National Science Foundation; and DOD R070HY (to
MDR) awarded by the Department of Defense. The government has certain rights in
the invention.

25

FIELD OF THE INVENTION

30 The present invention generally relates to the fields of neurology,
neuroscience, and endocrinology and to light systems, light meters, lamps, filters,
transparent and translucent materials, and methods of treating a variety of mammalian
disorders and, more particularly to a light system for stimulating or regulating
neuroendocrine, circadian, and photoneural systems in mammals based upon the
discovery of peak sensitivity ranging from 425-505 nm; a light meter system for
quantifying light which stimulates mammalian circadian, photoneural, and

BRA01-NP001**PATENT**

neuroendocrine systems; translucent and transparent materials, and lamps or other light sources with or without filters stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals; and treatment of mammals with a wide variety of disorders or deficits, including light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficit, hormone-sensitive cancers, and cardiovascular disorders.

BACKGROUND OF THE INVENTION

Light is the primary stimulus for regulating circadian rhythms, seasonal cycles, and neuroendocrine responses in many species including humans (Klein et al., 1991; Wehr, 1991). Further, clinical studies have demonstrated that light therapy is effective for treating selected affective disorders, sleep problems, and circadian disruptions (Wetterberg, 1993; Lam, 1998). Previously, the ocular photoreceptors which transduce light stimuli for circadian regulation and the clinical benefits of light therapy have been unknown.

Nonetheless, scientists have been deeply involved in elucidating the physiologic and functional anatomic features associated with light and vision. In fact, the underlying neuroanatomy and neurophysiology which mediate vision have been studied extensively over the past two centuries. More recently, the retinohypothalamic tract (RHT), a distinct neural pathway which mediates circadian regulation by environmental light, has been shown to project from the retina to the suprachiasmatic nuclei (SCN) in the hypothalamus. (Moore RY, Lenn NJ. A retinohypothalamic projection in the rat. *J Comp Neurol* 146:1-14, 1972; Moore RY (1983) Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. *Federation Proceedings* 42:2783-2789; Klein DC, Moore RY, Reppert SM, eds. *Suprachiasmatic Nucleus: The Mind's Clock*. Oxford: Oxford University Press, 5-456, 1991; Morin LP (1994) The circadian visual system. *Brain Res Brain Res Rev* 19:102-127). By this pathway, light and dark cycles are perceived through the mammalian eyes, entrain SCN neural activity and, in turn, entrain the rhythmic secretion of melatonin from the pineal gland. In virtually all

BRA01-NP001**PATENT**

species, melatonin secretion is high during the night and low during the day (Reiter, 1991; Arendt, 1998).

In addition to entraining pineal rhythms, light exposure can acutely suppress melatonin secretion (Rollag and Niswender, 1976; Lewy et al., 1980). A well-defined multisynaptic neural pathway extends from the SCN to the pineal gland, which transmits information about light and circadian time for entraining the rhythmic production and secretion of the hormone melatonin. (Moore RY, Lenn NJ. *J Comp Neurol* 146:1-14, 1972; Klein DC et al., eds. *Suprachiasmatic Nucleus: The Mind's Clock*. 5-456, 1991; Schwartz WJ, Busis NA, Hedley-Whyte ET. A discrete lesion of ventral hypothalamus and optic chiasm that disturbed the daily temperature rhythm. *J Neurol* 233:1-4, 1986; Arendt J. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. *Rev Reprod* 3: 13-22, 1998). In addition to synchronizing pineal indolamine circadian rhythms, ocular exposure to light during the night can acutely suppress melatonin synthesis and secretion (Klein DC, Weller JL (1972) Rapid light-induced decrease in pineal serotonin N-acetyltransferase activity. *Science* 177:532-533; Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP (1980) Light suppresses melatonin secretion in humans. *Science* 210:1267-1269). Light-induced melatonin suppression is a well-defined, broadly used marker for photic input to the RHT and SCN (Klein DC, 1991; Arendt J (1998) Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. *Rev Reprod* 3:13-22; Brainard GC, Rollag MD, Hanifin JP (1997) Photic regulation of melatonin in humans: ocular and neural signal transduction. *J Biol Rhythms* 12:537-546; Lucas RJ, Foster RG (1999) Neither functional rod photoreceptors nor rod or cone outer segments are required for the photic inhibition of pineal melatonin. *Endocrinology* 140:1520-1524).

Previously, it has not been known what photoreceptors transduce light stimuli for circadian regulation. Studies on animals with hereditary or light-induced retinal degeneration have raised the possibility that neither the rods nor the cones used for vision participate in light-induced melatonin suppression, circadian locomotor phase-shifts, or photoperiodic responses (Lucas, 1999; Webb SM, Champney TH, Lewinski AK, Reiter RJ (1985) Photoreceptor damage and eye pigmentation: influence on the sensitivity of rat pineal N-acetyltransferase activity and melatonin levels to light at night. *Neuroendocrinology* 40:205-209; Goto M, Ebihara S (1990) The influence of

BRA01-NP001

PATENT

different light intensities on pineal melatonin content in the retinal degenerate C3H mouse and the normal CBA mouse. *Neurosci Lett.* 108:267-272; Foster RG, Provencio I, Hudson D, Fiske S, DeGrip W, Menaker M (1991) Circadian photoreception in the retinally degenerate mouse (*rd/rd*). *J Comp Physiol [A]* 169:39-50; Freedman MS, Lucas RJ, Soni B, von Schantz M, Munoz M, David-Gray Z, Foster RG (1999) Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors. *Science* 284:502-504). Studies using rodents with retinal degeneration suggest that neither the rods nor cones used for vision participate in light-induced melatonin suppression, circadian phase-shifts, or photoperiodic responses (Pevet et al., 1984; Webb et al., 1985; Foster et al., 1991). Furthermore, enucleation of rod-less, cone-less transgenic mice abolishes light-induced circadian phase-shifts and melatonin suppression (Lucas and Foster, 1999; Freedman et al., 1999). Recently, light-induced melatonin suppression and circadian entrainment have been demonstrated in humans with complete visual blindness (Czeisler CA, Shanahan TL, Klerman EB, Martens H, Brotman DJ, Emens JS, Klein T, Rizzo JF, III (1995) Suppression of melatonin secretion in some blind patients by exposure to bright light. *N Engl J Med* 332:6-11) and with specific color vision deficiencies. (Ruberg, 1996). The study on humans with color vision deficiencies showed that protanopic and deuteranopic subjects who lacked functioning long wavelength-sensitive cones (red, or L cones), and middle wavelength cone photoreceptors (green, or M cones), exhibited normal light-induced melatonin suppression and entrainment of the melatonin rhythm (Ruberg FL, Skene DJ, Hanifin JP, Rollag MD, English J, Arendt J, Brainard GC (1996) Melatonin regulation in humans with color vision deficiencies. *J Clin Endocrinol Metab* 81:2980-2985). Thus, by themselves, neither the red nor green cone system could be the primary input for melatonin regulation, at least in humans with color vision deficiencies. Together, the results from human and animal circadian studies on different forms of visual blindness suggest that melatonin regulation by light is controlled, at least in part, by photoreceptors which differ from the photoreceptors that mediate vision.

Recent studies with various vertebrate species have identified several new molecules which may serve as circadian photopigments. These putative photopigments include both opsin-based molecules, such as vertebrate ancient (VA)

BRA01-NP001

PATENT

opsin and melanopsin, as well as non-opsin molecules like the cryptochromes (Soni BG, Foster RG (1997) A novel and ancient vertebrate opsin. *FEBS Lett* 406:279-283; Provencio I, Jiang G, De Grip WJ, Hayes WP, Rollag MD (1998) Melanopsin: an opsin in melanophores, brain, and eye. *Proc Natl Acad Sci U S A* 95:340-345; Miyamoto Y, Sancar A (1998) Vitamin B2-based blue-light photoreceptors in the retinohypothalamic tract as the photoactive pigments for setting the circadian clock in mammals. *Proc Natl Acad Sci U S A* 95:6097-6102). Among these new photopigments, only melanopsin has been specifically localized to the human retina. (Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD (2000) A novel human opsin in the inner retina. *J Neurosci* 20:600-605). The molecular identification of these candidate photopigments and their localization in the retina and/or neural components of the circadian system make them well-suited to act as circadian phototransducers. Functional data confirming their direct role in circadian photoreception, however, have been lacking.

The present invention required determining whether or not the three cone system, which supports photopic (daytime) vision, was also the primary input for pineal melatonin suppression in humans with normal, healthy eyes. The peak wavelength sensitivity of the photopic visual system is near 555 nm. (Rodieck RW (1998) *The First Steps in Seeing*, Sunderland, Massachusetts: Sinauer Associates, Inc.). If melatonin regulation were mediated primarily by the three cone photopic visual system, then 555 nm light would be the most potent wavelength for regulating melatonin secretion.

In the present invention, data show that 505 nm is approximately four times stronger than 555 nm in suppressing melatonin. These results demonstrate that the ocular photoreceptor primarily responsible for pineal melatonin regulation in humans, is not the cone system that is believed to mediate photopic vision. This present invention involved the first test of a specific photoreceptor system for melatonin regulation in humans with healthy, intact eyes.

Developing an action spectrum is a fundamental means for determining the input physiology for the circadian system. This photobiological technique has high utility for 1) defining the relative effectiveness of photons at different wavelengths for eliciting a biological response, and 2) identifying the specific photopigment involved in that response. (Lipson, 1994; Coohill, 1999). The specific aim of the present study

BRA01-NP001

PATENT

was to characterize the wavelength sensitivity of the photoreceptor system responsible for providing circadian input to the human pineal gland by establishing an action spectrum for light-induced melatonin suppression. The experiments defined an action spectrum that fits a retinaldehyde opsin template and identified 446-477 nm as the most potent wavelength region for regulating melatonin. Univariate among the eight fluence-response curves suggests that a single photopigment is primarily responsible for melatonin suppression. These results suggest that there is a novel photopigment in the human eye which mediates circadian photoreception.

Light as a therapeutic stimulus

Numerous studies have shown that environmental light is the primary stimulus for regulating circadian rhythms, seasonal cycles, and neuroendocrine responses in many mammalian species including humans (Klein et al., 1991; Morin, 1994; Czeisler, 1995). During the past 20 years, studies have tested the use of light for treating fall and winter depression (Seasonal Affective Disorder or SAD), nonseasonal depression, sleep disorders, menstrual dysfunction, and eating disorders. In addition, investigators are exploring the use of light for re-entraining human circadian physiology relative to the challenge of shift work or intercontinental air travel. A Congressional report estimated that there are 20 million shift workers in the United States. (US Congress, 1991). The two most common problems associated with shift work are reduced alertness on the job and reduced sleep quality after work. In addition, shift workers have increased health problems including higher risk of cardiovascular disease and gastrointestinal distress as well as cognitive and emotional problems. Chronic desynchronization of the circadian system is cited as one of the causes for these problems. (US Congress, 1991).

Light is known to be a potent stimulus for entraining and phase-shifting circadian rhythms in many species, including humans. (Czeisler et al., 1986; Klein et al., 1991). The circadian response to light is dependent on the stimulus intensity, wavelength and time of delivery. A phase-response curve (PRC) describes light-induced shifts in rhythms relative to the circadian phase when the light is given, and PRCs to light share similarities across many species.

BRA01-NP001

PATENT

Working from the human PRC to light, some investigators have tested strategies of light treatment to improve circadian entrainment thereby enhancing performance, alertness, and health in shift workers. Studying simulated shift work, different groups of investigators have shown that workers had accelerated circadian re-entrainment, enhanced alertness, and improved sleep quality after treatment with bright light (2,000 lux to 12,000 lux) versus dimmer light (10 lux to 150 lux).

Light stimulation of the circadian and neuroendocrine systems

Over the last two centuries, extensive research has elucidated the neuroanatomy and neurophysiology which support the sensory capacity of vision in mammals. More recently, animal studies have demonstrated a neural pathway, named the retinohypothalamic tract (RHT), which projects from the retina into the hypothalamus. (Moore and Lenn, 1972; Klein et al., 1991). Information about light is transmitted from the retina to the hypothalamic suprachiasmatic nuclei (SCN) which are fundamental circadian oscillators that regulate daily rhythms. (Klein et al., 1991). The pathways supporting vision and circadian regulation are anatomically separate, but there may be a link between these systems by a projection from the intergeniculate leaflet to the SCN. (Morin, 1994). Although the detailed neuroanatomy of the circadian system primarily has been determined with animal studies, parallel clinical and post-mortem studies suggest that humans have a similar circadian neuroanatomy. (Schwartz et al., 1986).

The circadian system controls daily rhythms of sleep, wakefulness, body temperature, hormonal secretion, and other physiological parameters. (Klein et al., 1991; Morin, 1994; Lam, 1998). There is considerable evidence from studies on mammals that the circadian and neuroendocrine effects of light are mediated via photoreceptive physiology in the eye as opposed to photoreceptive physiology in the skin or some other part of the body. A study by Campbell and Murphy (1998), however, reported that a 3 hour bright light pulse of 13,000 lux delivered to the backs of the knees of human subjects systematically reset circadian rhythms of body temperature and melatonin. In contrast, two recent studies failed to elicit acute melatonin suppression with similar bright light exposure to the backs of the knees in

BRA01-NP001

PATENT

healthy humans and an attempt to replicate Campbell and Murphey's findings failed to demonstrate a phase-shift after light exposure to the back of the. Further work is needed to determine whether or not the eyes are the exclusive sites for circadian photoreception in humans and other mammalian species. Data suggest that the eyes are the primary (if not exclusive) site for circadian and neuroendocrine phototransduction. Although light is the principal stimulus for regulating the circadian system, other external stimuli such as sound, temperature, social cues and conditioning may also influence physiological timing functions.

Light regulation of melatonin

A well-defined neural pathway carries photic information about light extends from the SCN to the pineal gland via a multisynaptic pathway with connections being made sequentially in the paraventricular hypothalamus, the upper thoracic intermediolateral cell column, and the superior cervical ganglion. (Moore, 1983). By way of this neuroanatomy, cycles of light and dark which are perceived through the eyes entrain SCN neural activity which, in turn, entrains the rhythmic synthesis and secretion of melatonin from the pineal gland. In virtually all species including humans, high levels of melatonin are secreted during the night and low levels are secreted during the day.

In addition to entraining the melatonin circadian rhythm, light can acutely suppress melatonin secretion. Specifically, exposure of the eyes to light during the night causes a rapid decrease in the high activity of the pineal enzyme serotonin-N-acetyltransferase and subsequent inhibition of synthesis and secretion of melatonin. The acute light-induced suppression of melatonin was first observed in rats and later in humans (Klein and Weller, 1972; Lewy et al., 1980). This response has been used as a tool by the PI (GCB) and many other investigators to help determine the ocular, neural and biochemical physiology for melatonin regulation. (Klein et al., 1991; Brainard et al., 1997). In addition, seasonal changes in photoperiod length alters the duration of the elevated melatonin production. Specifically, in a number of mammalian species including humans, the duration of increased nocturnal melatonin secretion is shorter in the summer due to shortened night time periods. In summary,

BRA01-NP001

PATENT

many studies have shown that light stimuli are the strongest and most consistent regulators of melatonin. In addition, certain drugs can powerfully impact melatonin secretion, while other non-photic and non-pharmacologic stimuli that may modify melatonin levels include body posture and exercise.

Phototransduction and action spectrum analysis

The overall aim of the present invention is the identification of the photoreceptor(s) for applications in the areas of circadian regulation, neuroendocrine regulation, and the clinical benefits of light therapy in humans. Fundamentally, all photobiological responses are mediated by specific organic molecules that absorb photons and then undergo physical-chemical changes which, in turn, lead to broader physiological changes within the organism. This photobiological process is termed phototransduction and the organic molecules which absorb light energy to initiate photobiological responses are called photopigments. Generally, these photoactive molecules do not absorb energy equally across the electromagnetic spectrum. Each photoreceptor molecule or complex has a characteristic absorption spectrum which depends on its atomic structure. An action spectrum is one of the main tools for identifying the photopigment which initiates a photobiological response. The simplest definition of an action spectrum is the relative response of an organism to different wavelengths. (Lipson, 1994; Coohill, 1999).

Photobiologists have evolved a refined set of practices and guidelines for determining analytical action spectra which are applicable to all organisms from plants to humans. (Coohill, 1991; Lipson, 1994). Analytical action spectra are developed using two or more monochromatic light stimuli with half-peak bandwidths of 15 nm or less. Generally, these action spectra are determined by establishing a set of dose-response curves (fluence-response curves) at different wavelengths for a specific biological response. The action spectrum is then formed by plotting the reciprocal of incident photons required to produce the criterion biological response versus wavelength. This fundamental photobiological technique has high utility for 1) defining the relative effectiveness of different wavelengths for eliciting a biological response, and 2) identifying the specific photosensitive molecules involved in

biological responses.

5 *Action spectra for circadian regulation in rodents*

As in other fields of photobiology, the initial attempts to define circadian and neuroendocrine responses to wavelength began with polychromatic action spectra which tested broader bandwidths of light in various rodent species (Coohill, 1991).
10 These polychromatic action spectra were published mainly during the early 1970's through the mid 1980's and were reasonably consistent in indicating that the spectral region between 450 nm and 550 nm provides the strongest stimulation of circadian and neuroendocrine responses in rodents (for review: Brainard et al., 1999). Analytic action spectra, however, are superior to polychromatic action spectra for identifying
15 the photopigments that mediate photobiological responses.

In a landmark study, Takahashi and colleagues determined an analytic action spectrum for circadian wheel running behavior in Syrian hamsters (Takahashi et al., 1984). Their study established fluence-response functions for a set of monochromatic wavelengths and then formed an action spectrum from those fluence-response
20 functions. Their action spectrum had a spectral peak ($\lambda_{\max}$) around 500 nm and seemed similar in shape to the absorption spectrum for rhodopsin. Although they found these data to support the hypothesis that a rhodopsin-based photopigment and rod cells in the retina mediate circadian entrainment in hamsters, they were careful to point out that the participation of a cone mechanism could not be excluded. Since
25 then, three other analytic action spectra have been published on circadian and neuroendocrine regulation in rodents. (Bronstein et al., 1987; Provencio and Foster, 1995; Yoshimura and Ebihara, 1996). Data from these action spectra have been fitted to spectral sensitivity curves for retinal-based visual photopigments. This curve fitting is predicated on the assumption that a retinal-based molecule transduces light
30 stimuli for circadian regulation, and allows the prediction of the shape of the photopigment absorption spectrum as well as its peak sensitivity ($\lambda_{\max}$). Across these rodent studies, the predicted $\lambda_{\max}$ ranges from 480 nm to 511 nm and is surrounded by a broad region of high sensitivity. From these studies, different

BRA01-NP001

PATENT

photopigments have been suggested to be responsible for circadian regulation including rhodopsin, a rhodopsin-like molecule, a middle wavelength cone photopigment, or a UV cone photopigment . Furthermore, preliminary data from other investigators working with Takahashi, showed that the action spectrum for photoperiod-dependent reproductive development response of male Siberian hamsters and light-induced phase-shifting of circadian locomotor activity has its λ_{max} in the range of 475 nm. The investigators interpret their unpublished action spectra to support the hypothesis that a short wavelength-sensitive photoreceptor mediates both functions. (Fred Turek, PhD, personal communication).

Circadian regulation in rodents with loss of cone and rod photoreceptors

It is important to note that there is considerable diversity in the cellular structure and function of the retina across mammalian species, and that in rodents the retina contains both cone and rod photoreceptors. (Rodieck, 1998). Early studies with blind mole rats and rats with destruction of retinal photoreceptors due to prolonged light exposure raised the possibility that neither the rods nor the cones used for vision participate in regulating the circadian and neuroendocrine systems. (Pevet et al., 1984; Webb et al., 1985). Despite profound loss of photoreceptors and vision, light detection for circadian and photoperiodic regulation was preserved. It remained possible, however, that a small population of surviving rods or cones could still be responsible for circadian photoreception.

Studies in mice with hereditary retinal disorders (*rd/rd* and *rds/rds*) have shown that these animals still exhibit normal light-induced melatonin suppression and circadian locomotor phase-shifts despite a nearly total loss of classical visual photoreceptors. The data support the conclusion that circadian photoreception is maintained either by 1) a very small number of rod or cone cells, or 2) an unrecognized class of retinal photoreceptors. (Foster et al., 1991; Provencio et al., 1994; Yoshimura et al., 1994). Further work with *rd* mice suggested that middle-wavelength sensitive (M-cones) and/or S-cones may be responsible for circadian photoreception. (Provencio and Foster, 1995; Yoshimura and Ebihara, 1996). Recent studies with transgenic coneless (*cl*) mice which have extensive loss of M-cones and

BRA01-NP001

PATENT

S-cones show that these mice exhibit normal sensitivity for light-induced melatonin suppression and circadian phase-shifting of locomotion. (Lucas et al., 1999; Freedman et al., 1999). Similarly, coneless, rodless mice (*rd/rd cl*) also appeared to exhibit normal sensitivity for light-induced melatonin suppression and phase-shifting of wheel-running behavior. These results indicate that rods, M-cones and S-cones are not required for circadian photoreception. Removal of the eyes however, abolished light-induced circadian phase-shifting. (Freedman et al., 1999). Overall the results suggest that the mouse eye contains specific photoreceptors for circadian regulation different from the visual photoreceptors. A study on normal rats, however, shows that the rod and cone photoreceptors for vision provide input to SCN neurons. (Aggelopoulos and Meissl, 2000). Thus, it is premature to rule out the visual photoreceptors from playing a role in circadian regulation in animals with normal, intact eyes.

If the rods and cones that mediate vision in rodents are not the primary photoreceptors for circadian regulation in rodents, what are the alternative candidates? Recent studies with various vertebrate species have identified several new molecules which may serve as circadian photopigments. These putative photopigments include both opsin-based molecules such as vertebrate ancient (VA) opsin (Soni and Foster, 1997), melanopsin (Provencio et al., 1998), and peropsin (Sun et al., 1997) as well as non-opsin molecules like biliverdin (Oren, 1996) and cryptochrome (Miyamoto and Sancar, 1998). Among these new photopigments, only melanopsin has been specifically localized to the human neural retina (Provencio et al., 2000) and cryptochrome has been localized to the mouse neural retina (Miyamoto and Sancar, 1998). The molecular identification of these candidate photoreceptors and their localization in the retina and/or neural components of the circadian system, make them well-suited to act as circadian phototransducers.

In summary, the present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm. Also, the present invention involves a light meter system for quantifying light which stimulates mammalian circadian, photoneural, and neuroendocrine systems, wherein the light meter has at least one light metering device to match peak wavelength sensitivity of mammalian photoreceptors for mammalian circadian, photoneural, and

BRA01-NP001

PATENT

neuroendocrine systems. Furthermore, the present invention exploits this peak wavelength sensitivity for novel light systems, novel translucent and transparent materials, and novel lamps or other light sources with or without filters. The present invention also involves the peak sensitivity as the focal point for treatment of mammals with a wide variety of disorders or deficits, including but not limited to, light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficit, hormone-sensitive cancers, and cardiovascular disorders.

DEFINITIONS

“Light responsive disorders” means any disorder responding to or preventable by phototherapy and includes, but is not limited to, seasonal affective disorders, sleep disorders, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers (including, but not limited to, breast cancers), and cardiovascular disorders.

“Light system” means a lamp, a lamp with filters, or another system or source for delivering light.

“Translucent or transparent material component” or “translucent or transparent material” includes, but is not limited to, at least one of the following: glasses, visors, windows, contacts, and filters. These materials may shape natural or artificial light.

“Light source” includes, but is not limited to, at least one of the following light sources: artificial light, natural light, and lamps.

SUMMARY OF THE INVENTION

The present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm. Also, the present invention involves a light meter system for quantifying light which stimulates mammalian circadian, photoneural, and neuroendocrine systems, wherein the light meter has at

BRA01-NP001**PATENT**

least one light metering device to match peak wavelength sensitivity of mammalian photoreceptors for mammalian circadian, photoneural, and neuroendocrine systems, said peak wavelength ranging between 425-505 nm. Furthermore, the present invention exploits this peak wavelength sensitivity for novel light systems, novel translucent and transparent materials, and novel lamps or other light sources with or without filters. The present invention also involves exploiting this peak sensitivity for treatment of mammals with a wide variety of light responsive disorders or deficits, including but not limited to, light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficit, hormone-sensitive cancers, and cardiovascular disorders.

The light metering device is specifically configured to accurately quantify electromagnetic radiation that stimulates or regulates the circadian, photoneural, and neuroendocrine systems of healthy mammals or mammals having a variety of disorders. The meter's wavelength sensitivity matches the wavelength sensitivity of the photoreceptors for circadian, photoneural, and neuroendocrine regulation in mammals. This device is also used to quantify electromagnetic radiation which is optimum for treating Seasonal Affective Disorders (SAD) or other light-responsive disorders.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1: In this graph the bars represent group mean + SEM plasma melatonin values (N=8) before and after monochromatic light exposure at 505 nm. There were no significant variations across mean melatonin pre-light exposure values ($F=0.85$). Paired, two-tailed Students' t tests demonstrated which light intensities elicited a significant melatonin suppression.

Fig. 2: This graph illustrates group mean + SEM % control-adjusted melatonin change values (N=8) at 505 nm monochromatic light exposure. The figure shows that progressively higher light irradiance exposure produces increasingly greater melatonin suppression.

Fig. 3: This figure demonstrates the fitted fluence-response curve for photon density and % control-adjusted melatonin suppression (N=8). Each data point represents one group mean $\pm$ SEM.

BRA01-NP001

PATENT

Fig. 4: The bars represent group mean + SEM values relative to an equal photon dose of 4.2×10^{13} photons/cm². These data show that the 505 nm % control-adjusted plasma melatonin suppression is significantly stronger than that for 555 nm.

Fig. 5: This diagram illustrates the experimental electronic, optic and ganzfeld dome exposure array. This apparatus provides a uniform, patternless stimulus that encompasses the subject's entire visual field. For clarity, the subject's head is shown slightly withdrawn from the opening of the ganzfeld dome. During all light exposures, the subjects' bony orbits are completely enclosed in the dome walls providing complete exposure of their visual fields.

Fig. 6: In this graph the bars represent group mean + SEM plasma melatonin values before and after monochromatic light exposure at 460 nm in eight healthy subjects. There were no significant differences ($F=0.70$, $p=0.69$) across pre-exposure mean melatonin values. Light irradiances at or above $3.1 \mu\text{W}/\text{cm}^2$ elicited significant melatonin suppression.

Fig. 7: This figure illustrates the mean + SEM plasma melatonin percent control-adjusted change scores from eight healthy subjects exposed to different irradiances of monochromatic light at 460 nm. Progressively higher irradiance exposures at 460 nm produce progressively greater plasma melatonin percent control-adjusted change scores ($p<0.0001$).

Fig. 8: This graph demonstrates the best fit fluence-response curve for 460 nm exposures and percent control-adjusted melatonin suppression ($R^2 = 0.97$). Each data point represents one group mean $\pm$ SEM from eight healthy subjects.

Fig. 9: This figure illustrates the fitted univariant fluence-response curves for monochromatic light exposures and percent control-adjusted melatonin suppression for eight wavelengths of visible light. Each fluence-response curve is derived from eight healthy volunteers who participated in a complete, within-subjects experimental design. In each graph, the data points represent group means $\pm$ SEM. Each curve has a high coefficient of correlation (0.95 to 0.81).

Fig. 10: In this graph the bars represent group mean + SEM plasma melatonin values before and after exposure to $31.8 \mu\text{W}/\text{cm}^2$ monochromatic light at 420 nm in eight healthy subjects. This light irradiance induced a significant melatonin suppression ($p<0.003$).

BRA01-NP001

PATENT

Fig. 11: This graph demonstrates the action spectrum for percent control-adjusted melatonin suppression in 72 healthy human subjects. The filled circles represent the half-saturation constants of eight wavelengths from 440 to 600 nm which were normalized to the maximum response and plotted as log relative sensitivity. The open circle represents the estimated half-saturation constant derived from the 420 nm data. The line in the graph portrays the best fit template for vitamin A₁ retinaldehyde photopigments which predicts a maximal spectral absorbance (I_{max}) of 464 nm (Partridge and De Grip, 1991). There is a high coefficient of correlation for fitting this opsin template to the melatonin suppression data ($R^2 = 0.91$). The basis for the balanced wavelength peak sensitivity range is a calculation of approximately two standard deviations from 464 nm.

Fig. 12: This figure illustrates a comparison of the melatonin suppression and visual action spectra. The maximal spectral response and long wavelength limb of the melatonin suppression template is plotted along with the maximal spectral response and long wavelength limbs of the human rods and cones that support vision (Stockman and Sharpe, 1999). The shaded area around the 464 nm template represents $\pm$ SD from the data presented above.

DETAILED DESCRIPTION

The science of photobiology involves the study of how the infrared, visible and ultraviolet portions of the electromagnetic spectrum influence biological processes. There are two broad categories of light measurement techniques: radiometric and photometric. Each measurement technique has its merits and drawbacks relative to circadian regulation, neuroendocrine regulation and light therapy. Radiometry is based exclusively on the physical properties of light - its energy and wavelength. A radiometer measures the radiant power of a light source over a defined range of wavelengths. Radiometers can be configured to measure different bandwidths across the electromagnetic spectrum. The wavelengths within

BRA01-NP001**PATENT**

the designated bandwidth can be detected equally, or they can be filtered for differential sensitivity across the various wavelengths.

In contrast to radiometry, photometry is based on the selective responsiveness of the human visual system. A photometer is simply a radiometer that has filters added to the detector which "shape" the detector sensitivity to resemble the luminance (brightness) response of the human visual system. Thus, photometry is a special branch of radiometry. Between individual humans, there are substantial differences in visual responses. The average photopic and scotopic visual functions are defined with reference to the adaptive state of the rod and cone photoreceptors in the human retina. Radiometers can be filtered to detect only those relative proportions of wavelengths that comprise the photopic or scotopic visual response. Photometers will detect photopic lux or scotopic lux, respectively. Specifically defined, lux measures are measures of illuminance - the amount of light, or luminous flux, falling on a surface. One photopic lux is one lumen per square meter (lm/m^2). The new metering system is configured to measure a new lighting unit which could be called "circadian lux" as opposed to photopic lux or scotopic lux.

Most investigators have operated from the assumption that light therapy is mediated via a photoreceptive mechanism in the human eye as opposed to a photoreceptive mechanism in the skin or some other part of the body. The data of the present invention demonstrate that the photoreceptive mechanism for the circadian and neuroendocrine system or the photoreceptive mechanism that mediates light therapy is not identical to the photoreceptive system that mediates the sensory capacity of vision.

Subjects, Materials and Methods

Subjects

The healthy females (N=6) and males (N=10) in this study had a mean $\pm$ SEM age of 25.7 ± 0.8 yrs, demonstrated normal color vision as measured by the Ishihara and Farnsworth Munsell D-100 tests (mean FM score: 64.2 ± 11.5), had a stable

BRA01-NP001**PATENT**

sleeping pattern (mean wake-up time 7:30 AM $\pm$ 12 min), and signed an approved IRB consent document before participating.

Light exposure protocol

Each experiment began at midnight when subjects entered a dimly lit room (10 lux). One drop of 0.5% Cyclopentolate HCl was placed in each eye to dilate the pupils, and blindfolds were placed over subjects' eyes. Subjects remained sitting upright in darkness for 120 min. While still blindfolded and just prior to 2:00 AM, a blood sample was taken by venipuncture. During light exposure, each subject's head rested in an ophthalmologic head holder facing a Ganzfeld apparatus that provided a concave, patternless, white reflecting surface encompassing the subject's entire visual field. The subjects were exposed to the light stimulus from 2:00 to 3:30 AM. During this 90 min exposure, subjects sat quietly, kept their eyes open and gazed at a fixed target dot in the center of the Ganzfeld dome. Subject compliance for keeping their eyes open and the subjects' pupil size were monitored by a miniature video camera. At 3:30 AM, a second blood sample was taken. Each subject was exposed to complete darkness from 2:00 to 3:30 AM on their control night and was tested with at least 6 days between each nighttime exposure. Plasma samples were assayed for melatonin by RIA. (Rollag, 1976). The minimum detection limit of the assay was 0.5 - 2.0 pg/mL. Control samples had 8% and 14% intra-assay coefficients of variation.

Light production and measurement

Experimental light stimuli were produced by xenon arc lamps (Photon Technology Int'l , Inc., Princeton, NJ) enclosed in a light-proof chamber and cooled by high-speed fans and water circulation. An exit beam of light from each source was directed by a parabolic reflector, and excess heat in this beam was reduced by a water filter. Monochromatic wavelengths (10-11 nm half-peak bandwidth) were produced by a grating monochromator and light irradiance was controlled by a manual diaphragm. The resulting light beam was directed into the top area of a Ganzfeld dome and reflected evenly off the walls into volunteers' eyes. The entire reflecting

BRA01-NP001**PATENT**

surface of the dome was coated with a white surface with a 95-99% reflectance efficiency over the 400 to 760 nm range. Routine measurement of the light irradiance ($\mu\text{W}/\text{cm}^2$) was done with a J16 Meter with a J6512 irradiance probe (Tektronix, Beaverton, OR). Experimental light stimuli reflected from the Ganzfeld domes were measured at volunteers' eye level immediately before and after the 90 min exposure. Additional measures were taken each half hour of the exposure to insure stimulus stability and enable intensity readjustment. Subjects in the 505 nm series were exposed to intensities ranging from 0.011 to $97 \mu\text{W}/\text{cm}^2$ (a 3 log unit photon density range of 10^{10} to 10^{13} photons/ cm^2). Subjects exposed to 555 nm received control or a $15 \mu\text{W}/\text{cm}^2$ (4.2×10^{13} photons/ cm^2) exposure.

Statistics

Two-tailed, Students' t tests were used to assess significance of raw melatonin change from 2:00 to 3:30 AM. These data were then converted to % control-adjusted melatonin change scores as described elsewhere. (Gaddy, 1993). For the 505 nm data, sets of pre-exposure melatonin values and % control-adjusted melatonin change scores were analyzed with one-way, repeated measures ANOVA. Significant differences between groups were assessed with post-hoc Scheffe F-tests; alpha was set at 0.05. For the 505 nm mean % control-adjusted melatonin suppression data, the computer program Origin 6.0 (Microcal, Northampton, MA) was used to fit a fluence-response curve to a 4 parameter model as described elsewhere (Brainard, 19893), and to test for goodness-of-fit of the data by coefficient of correlation.

Results

The full 505 nm data complement, from raw melatonin values to a final fluence-response curve, is illustrated in **Figs. 1-3**. Across all nights of testing, there were no significant differences ($F=0.85$) between sets of pre-exposure melatonin values indicating that plasma levels were consistent across the different study nights. **Fig. 1** shows the mean $\pm$ SEM pre- and post-exposure melatonin values. One-way,

BRA01-NP001

PATENT

repeated measures ANOVA showed a significant effect of light intensity on plasma melatonin % change scores ($F=17.17$, $P<0.0001$). Paired t tests demonstrated that compared to the $0 \mu\text{W}/\text{cm}^2$ control night, all intensities at or above $5.5 \mu\text{W}/\text{cm}^2$ significantly suppressed melatonin ($P<0.05$ or less). In contrast, irradiances of 2.8, 1.4 and $0.011 \mu\text{W}/\text{cm}^2$ did not suppress melatonin compared to the control night (Scheffe F values: 0.97, 0.01 and 0.02, respectively). As illustrated in Fig. 2, all melatonin data were converted to control-adjusted % change scores. As with the melatonin % change scores, ANOVA showed a significant effect of light intensity on plasma melatonin % control-adjusted change scores ($F=13.59$, $P<0.0001$). Fig. 3 illustrates a best fit, sigmoidal fluence-response curve which plots melatonin % control-adjusted scores against stimulus photon density. The specific formula for this curve is included in the figure.

Subjects exposed to 555 nm received both control ($0 \mu\text{W}/\text{cm}^2$) and $15 \mu\text{W}/\text{cm}^2$ (4.2×10^{13} photons/ cm^2) exposures. For the control and light exposure nights, the mean pre-exposure raw melatonin scores were 64.4 ± 12.5 and 59.6 ± 6.2 , while the mean post-exposure scores were 62.6 ± 10.5 and 49.1 ± 6.0 , respectively. The modest drop in melatonin over the 90 min 555 nm light exposure period was not statistically significant ($t=1.69$, $df=7$, $P=0.14$). For comparison of responses to 505 nm and 555 nm, Fig. 4 illustrates % control-adjusted melatonin suppression relative at equal photon densities across the two wavelengths. These data reveal that 505 nm is significantly stronger than 555 nm in suppressing melatonin ($t=-3.04$, $df=14$, $P<0.01$).

Discussion

The data presented here demonstrate that: 1) there is a clear fluence-response relationship between graded light intensities of 505 nm light and melatonin suppression, and 2) that 505 nm light is significantly stronger than 555 nm light for suppressing melatonin in healthy, human subjects. Previous studies with animals and humans have illustrated fluence-response relationships for melatonin suppression and circadian phase-shifting with exposure to monochromatic light (Podolin, 1987; Brainard, 1988; Nelson, 1991) as well as white light (Brainard, 1983; Boivin, 1996). A recent study on human subjects suggests that a four parameter curve is optimal for

BRA01-NP001**PATENT**

modeling light-induced melatonin suppression and circadian phase shifting. (Zeitzer, 1997). That contention matches earlier animal data (Brainard, 1983) as well as the 505 nm data reported here.

The demonstration that 505 nm light is more potent than 555 nm light for controlling melatonin has important basic science and clinical implications. In humans, it is well-established that higher levels of ocular illumination are required for stimulating the circadian system than for supporting vision. (Lewy, 1980, Nelson, 1991; Czeisler, 1986). Consequently, many investigators have considered the three cone photopic visual system to be responsible for stimulating circadian and neuroendocrine responses since this part of the visual system is responsive to "bright" daytime levels of illumination. Over the past 20 years most of the published literature on human circadian responses to light reports light levels in terms of illuminance (lux, lumens) which is a specific measure based on the traditional sensitivity curve of the photopic visual system. The peak wavelength sensitivity of that curve is 555 nm. (Rodieck, 1998). Indeed, some researchers have argued that their data support the notion that the visual cones are involved in circadian phase-shifting in humans. (Zeitzer, 1997). If melatonin regulation is mediated primarily by the three cone photopic visual system, then 555 nm light should be the most potent wavelength for regulating melatonin. The data here do not support this view. On the contrary, 505 nm is significantly stronger, photon for photon, than 555 nm in suppressing melatonin. The clinical implication of this result is that it is not optimum to use photometric values (lux) for quantifying light used therapeutically in patients with certain sleep disorders or circadian disruption due to shiftwork or intercontinental jet travel as is the current standard practice. (1995 Special Issue, J Biol).

Ultimately, these studies open the door for redefining how light should be measured relative to the circadian system. The best circadian measurement system would match the action spectrum for human circadian regulation. That action spectrum would not only elucidate the relative circadian potencies of different wavelengths, but it should help identify the photoreceptor that initiates signals from the retina to the SCN.

In summary, monochromatic 505 nm light suppressed melatonin in a fluence-response manner, and is approximately four times stronger than a 555 nm stimulus at

BRA01-NP001

PATENT

an equal photon dose for melatonin suppression. These data demonstrate that the three cone system that is believed to mediate human photopic vision is not the primary photoreceptor system to transduce light stimuli for melatonin regulation.

5

Action Spectra Study design

10

Action spectra are determined by comparing the number of photons required for the same biological effect at different wavelengths (Lipson, 1994; Coohill, 1999). The melatonin suppression action spectrum described here was formed from fluence-response curves at 8 wavelengths between 440 nm and 600 nm. A within-subjects design was used for each fluence-response curve. For each wavelength studied, a set of 8 volunteers was exposed to a minimum of 8 different light irradiances on separate nights with at least 6 days between exposures. At the completion of that work, it was determined that a probe of sensitivity to monochromatic light below 440 nm was needed. Consequently, a group of 8 subjects was exposed to a single night of no light exposure and a single night of exposure to one irradiance of 420 nm light.

15

20

Subjects

25

30

Volunteers who were involved in shift work, planned long distance jet travel before or during the study period, or had irregular sleeping schedules were excluded from this study. The subject drop-out rate was 7.9%. The ethnic distribution of the 72 subjects who completed this study included 55 Caucasians, 9 Asians, 4 African Americans, 3 Hispanics and 1 individual of unknown ethnicity. Subjects who had a relatively stable daily sleeping pattern, passed a physical exam for general and ocular health, and signed an approved IRB consent document were accepted into this study. A total of 37 females and 35 males between 18-30 years old (mean $\pm$ SEM age = 24.5 $\pm$ 0.3) completed the study. The self-reported mean $\pm$ SE weekday wake-up time among subjects was 7:06 AM $\pm$ 18 min. All subjects were normal on the Ishihara and Farnsworth Munsell D-100 tests for color vision (mean $\pm$ SEM FM score: 51.4 $\pm$ 4.3).

Light exposure protocol for action spectra

Each experiment began at midnight when subjects entered a dimly lit room (10 lux or less). One drop of 0.5% Cyclopentolate HCl was placed in each eye to dilate the subjects' pupils and blindfolds were placed over their eyes. Subjects remained sitting upright for 120 minutes and listened to music on headphones or engaged in quiet conversation. While still blindfolded and just prior to 2:00 AM, a 10 ml blood sample was taken by venipuncture of the antecubital vein. Subjects' blindfolds were then removed and the subjects were exposed to the monochromatic light stimulus from 2:00 to 3:30 AM. During light exposure, each subject's head rested in an ophthalmologic head holder facing a ganzfeld apparatus that provided a concave, patternless reflecting surface encompassing each subject's entire visual field (see Figure 1). During this 90 minute exposure, subjects sat quietly, kept their eyes open and gazed at a fixed target dot in the center of the ganzfeld dome. Subject compliance for keeping their eyes open and the subjects' pupil size were monitored by a miniature video camera inside the ganzfeld dome. If the subjects began to close their eyes during the exposure period, the experimenters reminded them to keep their eyes completely open. At 3:30 AM, a second 10 ml blood sample was taken by venipuncture and the subjects were then permitted to leave the laboratory. Eight wavelengths were studied for this action spectrum (440, 460, 480, 505, 530, 555, 575 and 600 nm). Across these wavelengths, each subject was exposed to complete darkness from 2:00 to 3:30 AM on their control night and to a set of irradiances covering a 4 log unit photon density range of 10^{10} to 10^{14} photons/cm² on exposure nights. For the probe of sensitivity to monochromatic light at 420 nm, a group of 8 subjects were exposed to a single night of no light exposure and a single night of exposure to 420 nm light at 31.8 μ W/cm² (5.58×10^{13} photons/cm²).

Light production and measurement

As shown in Fig. 5, experimental light stimuli were produced by a 450 or 1200 W xenon arc lamp (Photon Technology Inc., Princeton, NJ). Each lamp was

BRA01-NP001

PATENT

enclosed in a light proof chamber and cooled by water circulation. An exit beam of light from each source was directed by a parabolic reflector and, for the 1200 W lamps, excess heat in the light beam was reduced by a water filter. Monochromatic wavelengths (10-14.5 nm half-peak bandwidths) were produced by a grating monochromator and light irradiance was controlled by a manual diaphragm. The resulting light beam was directed into the top area of a ganzfeld apparatus and reflected evenly off the walls of the ganzfeld dome into volunteers' eyes. The entire reflecting surface of the dome was coated with a white material (Spectralite) with a 95-99% reflectance efficiency over the 400 to 760 nm range. Routine measurement of the light irradiance ($\mu\text{W}/\text{cm}^2$) was done with a Tektronix J16 Radiometer/Photometer with a J6512 irradiance probe (Tektronix, Beaverton, OR). Experimental light stimuli reflected from the ganzfeld dome was measured at volunteers' eye level immediately before and after the 90 minute exposure. Additional measures were taken each half hour of the exposure to insure stimulus stability and enable readjustment of the intensity if it varied. These spot measures were taken with a ft-1° meter (Minolta, Osaka, Japan). Spectroradiometric assessment of the monochromatic wavelengths at the level of subjects' corneas was done with a portable spectroradiometer with a fiber optic sensor (Ocean Optics S2000). This equipment was calibrated with a standard lamp traceable to the National Institute of Standards and Technology (NIST).

In action spectroscopy, it is critical that the measured light stimuli are representative of the stimuli which actually reach the photoreceptors that mediate the photobiological response. In studies on light regulation of the circadian system, factors which can modify the measured stimulus before it reaches the photoreceptors include head and eye motion, squinting and eye closure, pupillary reflexes, and light transduction through the ocular media (Gaddy et al., 1993; Brainard et al., 1997). Most of these factors are controlled in the experimental technique described above. Concerning light transmission through ocular media, the cornea and aqueous and vitreous humors normally transmit nearly 100% of visible wavelengths to the retina and do not change substantively as the eyes age (Boettner and Wolter, 1962). In contrast, the aging human lens develops pigmentation that attenuates the transmission of shorter visible wavelengths to the retina (Lerman, 1987; Brainard et al., 1997). In

BRA01-NP001

PATENT

the present study, restricting the age of volunteers to 18-30 years controlled this factor. Measurements of mean transmittance of 36 postmortem human lenses in this age range showed relatively even transmission from 440 to 600 nm. In contrast, there was a mean 45% reduction in lens transmission at 420 nm compared to 460 nm (Brainard et al., 1997). Consequently, measured corneal light irradiances at 420 nm had to be adjusted to compensate for reduced stimulus transmission to the retina even in this relatively young study group.

Blood samples and melatonin assay

Blood samples were collected in glass vacutainers which contained EDTA. Plasma was separated by refrigerated centrifugation, aliquoted into cryogenic vials and stored at -20° C until assay. Melatonin concentrations were assayed by radioimmunoassay using antiserum described by Rollag and Niswender, (1976). Radiolabeled ligand was prepared by adding 10 µl of a dioxane solution containing 1 µmole 5-methoxytryptamine and 1 µmole tri-N-butylamine to 250 µCi (0.1 nmole) dried Bolton-Hunter Reagent (New England Nuclear Corp., Boston, MA). The reaction was allowed to proceed for one hour before adding 50 µl of aqueous sucrose (16 gm/ml electrophoresis buffer) and purifying product by disc gel electrophoresis. Duplicate aliquots of 200 µl of each unknown and control sample were extracted into 2 ml of chloroform. The chloroform was removed in a SpeedVac centrifuge (Savant Instruments, Holbrook, NY) and resuspended in 200 µl of assay buffer (phosphate buffered saline, pH 7.4, containing 0.1% gelatin with 100 mg thimerosal/liter as a preservative). The extracts were washed twice with 3 ml of petroleum ether, then evaporated to dryness in a SpeedVac before being resuspended in 200 µl of deionized water. Approximately 50,000 cpm of radiolabeled ligand and a 1:256,000 dilution of antiserum (R1055, 9/16/74) was added to each unknown and a triplicate 2-fold geometric series of standards ranging in concentration from 0.201 to 200 pg per 200 µl assay buffer. The final assay volume of buffer in each tube was 400 µl. At the end of the 48 hour incubation period, three ml of 95% ethanol (4° C) was added to each assay tube and the bound radioactivity precipitated by centrifugation at 2000 x g for 30 minutes. The supernatant was decanted and radioactivity in the precipitate was

quantified. The quantity of melatonin immunoreactivity in the samples was calculated with the use of a computer program (M.L. Jaffe and Associates, Silver Spring, MD; see Davis et al., 1980). All solutions were maintained at 4° C throughout the radioimmunoassay procedure. Assay results were not corrected for recovery (which has proven to be >95% in independent trials). The minimum detection limit of the assay is 0.5-2.0 pg/ml.

Statistics for action spectra

Two-tailed, paired Student's t tests were used to assess statistical significance of raw melatonin change from 2:00 to 3:30 AM. Percent melatonin change scores were determined by the following formula:

$$\text{Percent Melatonin Change Score} = \frac{100 \times (03:30 \text{ h melatonin} - 02:00 \text{ h melatonin})}{02:00 \text{ h melatonin}}$$

Percent melatonin change scores then were normalized to percent control-adjusted change scores by subtracting the control (no light) condition percent change scores for each subject from that same subject's light exposure score. This technique accounts for the normal individual rise or fall in plasma melatonin levels with respect to the light-induced changes (Gaddy et al., 1993; Brainard et al., 1997). For data from each wavelength, complete sets of pre-exposure melatonin values, percent melatonin change scores, and percent control-adjusted melatonin change scores were analyzed with one way, repeated-measures ANOVA. Significant differences between groups were assessed with post-hoc Scheffe F-tests with alpha set at 0.05. The group of single fluence-response curves (one for each wavelength) was fitted to a parametric model in which the melatonin response (Y) to a photon dose (X) is predicted by: the theoretical initial Y-response (0 dose) for the curve (A₁); the theoretical final Y-response ("infinite" dose) for the curve (A₂); the dose producing a response halfway

BRA01-NP001

PATENT

between A₁ and A₂ (X₅₀ or ED₅₀); and the slope estimator (p) for the slope of the curve between A₁ and A₂. The equation is:

$$Y = \frac{A_1 - A_2}{1 + (X/X_{50})^p} + A_2$$

The computer program Origin 6.0 (Microcal, Northampton, MA) was used to fit the fluence-response curves to the data. From extensive experience in our laboratory, a saturating 90 minute light exposure produces a maximum mean percent control-adjusted plasma melatonin suppression ranging from 60 to 80% depending on the particular group of subjects being tested (Gaddy et al., 1993; Ruberg et al., 1996; Wang et al., 1999; Brainard et al., 2000; 2001). To form an analytical action spectrum, it is necessary to determine if all fluence-response curves can be fit to a univariant sigmoidal curve (Lipson, 1994; Coohill, 1991; 1999). To do this, sigmoid curves were fitted to the five fluence-response curves between 440 nm and 530 nm which reached a mean percent control-adjusted melatonin suppression of 60-80% by constraining the A₁ factor (theoretical initial Y-response) to 0 since no light exposure should yield a 0% control-adjusted plasma melatonin suppression. From this set of curves, a mean A₂ (theoretical final Y-response or "infinite" dose for the curve), and a mean p (slope estimator) was calculated. Subsequently, all 8 data sets (including the data sets which did not reach saturation) were then fitted to sigmoid curves that constrained A₂ and p to these means and constrained A₁ to 0. Each calculated curve was tested for goodness-of-fit of the data by coefficient of correlation.

Melatonin action spectrum

This action spectrum was formed from the photon density which elicited the half-saturation constant (ED₅₀) of the percent control-adjusted melatonin suppression for each of the 8 wavelengths. These half-saturation constants were derived from the 8 univariant fluence-response curves described above. The half-saturation constants

BRA01-NP001

PATENT

were then normalized to the maximum response and plotted as relative sensitivity. The relative quantum sensitivity from each group of subjects was then graphically plotted (quanta/wavelength) to illustrate the resultant action spectra for melatonin suppression in humans. A predicted peak sensitivity for this action spectrum was determined by fitting a vitamin A₁-retinaldehyde photopigment template to the data by a modification of the method described by MacNichol (1983). Specifically, the long wavelength limb of vitamin A₁-based photopigments can be considered linear within the 10-90% sensitivity range when plotted on a frequency abscissa. To select the best fit vitamin A₁ template, the normalized 10-90% long wavelength melatonin ED₅₀ data were fitted to a series of vitamin A₁-based templates within the 10-90% sensitivity range of the templates' long-wavelength limbs (Partridge and De Grip, 1991). Pearson correlation coefficients derived from fitting the melatonin data to the templates indicated the optimum fitting template.

Results of action spectra

Variations in pupillary dilation, exposure time and melatonin assay

Individuals vary slightly in their pupil size and response to mydriatic agents. Mean $\pm$ SD pupillary dilation was 7.19 ± 0.88 mm for all 72 subjects across all nights of exposures. There were no significant pupil size changes during the light exposures. Similarly, there is a small degree of variability in exact light exposure durations due to slight experimental delays. Across 627 single-subject experiments, the mean $\pm$ SD exposure duration was 90.6 ± 2.1 minutes. A total of 53 assays were run to quantify melatonin in plasma samples collected during this project. Coefficients of variation calculated from control samples assayed as 19.2 pg/ml and 90.0 pg/ml had 10.8% and 4.0% for intra-assay coefficients of variation, respectively. The inter-assay coefficients of variation were 13.5% and 10.2%.

Fluence-response data at 460 nm

Since the predicted peak of the final action spectrum is 464 nm, the full data complement, from raw melatonin values to a final fluence-response curve for the nearby monochromatic stimulus at 460 nm, is illustrated in **Figs. 2-4**. This fluence-response study at 460 nm was done with 8 subjects (4 males, 4 females). Across these subjects on all nights of testing, there were no significant differences ($F=0.70$, $p=0.69$) between sets of pre-exposure values indicating that baseline nocturnal melatonin levels were consistent across the different nights of study. **Fig. 6** shows the mean + SEM pre- and post-exposure (2:00 to 3:30 AM) melatonin values (mean range 72.1-29.3 pg/ml). At 460 nm, exposure to irradiances of $2.3 \mu\text{W}/\text{cm}^2$ and lower did not significantly suppress plasma melatonin. In contrast, exposures of $3.1 \mu\text{W}/\text{cm}^2$ and higher elicited significant melatonin suppressions ($p < 0.03$ or less).

For comparative purposes, all melatonin data were converted to plasma melatonin percent control-adjusted change scores. As illustrated in **Fig. 7**, one-way, repeated measures ANOVA showed a significant effect of light intensity on plasma melatonin percent control-adjusted change scores ($F=14.92$, $p<0.0001$). Post-hoc tests on plasma melatonin percent control-adjusted scores demonstrated that all intensities at or above $3.1 \mu\text{W}/\text{cm}^2$ significantly suppressed melatonin more than $0.012 \mu\text{W}/\text{cm}^2$ ($p<0.05$ or less). Similarly, all irradiances at or above $12.1 \mu\text{W}/\text{cm}^2$ significantly suppressed melatonin more than $1.5 \mu\text{W}/\text{cm}^2$. Finally, both 24.2 and $42.2 \mu\text{W}/\text{cm}^2$ exposures elicited significantly higher plasma melatonin percent control-adjusted change scores compared to an irradiance of $2.3 \mu\text{W}/\text{cm}^2$.

The data from **Fig. 7** can be mathematically converted into a best fit, sigmoidal curve which plots melatonin suppression against stimulus photon density. The specific formula for this curve is shown below and has a 0.97 coefficient of correlation (R^2).

$$y = \frac{7.17 - 73.4}{1 + (x/8.29)^{1.23}} + 73.4$$

As shown in **Fig. 8**, this curve illustrates the fluence-response interaction between mean $\pm$ SEM melatonin percent control-adjusted change scores and the photon density of the monochromatic light.

Fluence-response data for all 8 wavelengths

As shown in **Figs. 6-8**, there is a clear, fluence-response relationship between graded photon densities of monochromatic 460 nm light and melatonin suppression. Data from each of the 8 wavelengths tested in this study fit four-parameter sigmoidal curves with high coefficients of correlation. Specifically, wavelengths at 440, 460, 480, 505, 530, 555, 575 and 600 nm had respective coefficients of correlation (R^2): 0.99, 0.97, 0.95, 0.97, 0.98, 0.92, 0.96, and 0.97. As described in the Methods, to form an analytical action spectrum, all fluence-response curves must be fit to a univariant sigmoidal curve (Lipson, 1994; Coohill, 1999). The univariant curve model for the data in this study has the factors of $A_1=0$, $A_2=66.9$, and $p=1.27$. Figure 5 illustrates all 8 univariant fluence-response curves from this study. As with previous circadian analytical action spectra (Takahashi et al., 1984; Provencio and Foster, 1995; Yoshimura and Ebihara, 1996), full range fluence-response curves were not elicited above 550 nm. Despite this, standard photobiological curve fitting methods could be used to fit the data from all eight wavelengths in the present study to univariant, sigmoidal functions. When fit to a univariant fluence-response curve with these factors, the data from exposures to 440, 460, 480, 505, 530, 555, 575 and 600 nm have high coefficients of correlation of 0.91, 0.95, 0.93, 0.94, 0.92, 0.90, 0.95, and 0.81, respectively.

Melatonin suppression response to 420 nm at a single intensity

Given the high sensitivity of subjects to short wavelength light as shown in **Fig. 9**, it was determined that a probe of sensitivity to monochromatic light below 440 nm was needed. On the control night when the eight volunteers were exposed to

darkness only, their raw mean melatonin levels at 2:00 and 3:30 AM were 69.4 and 76.0 pg/ml, respectively. That small increase was not statistically significant ($t=-1.15$, $p=0.29$). As shown in **Fig. 10**, when these volunteers were exposed to 420 nm light at 31.8 $\mu\text{W}/\text{cm}^2$ (5.58×10^{13} photons/ cm^2), raw mean melatonin levels at 2:00 and 3:30 AM were 76.4 and 47.6 pg/ml, respectively. That decrease in melatonin was statistically significant ($t=4.67$, $p<0.003$). For comparative purposes, this single melatonin suppression response was fitted to the univariant fluence-response curve formula used for all of the data in **Fig. 9**. The resulting curve estimated a half-maximum (X_{50} or ED_{50}) melatonin suppression response for 420 nm of 1.83×10^{13} photons/ cm^2 .

Action spectrum for melatonin suppression

Action spectra are determined by comparing the number of photons required for the same biological effect at different wavelengths (Smith, 1989; Coohill, 1999). For this experiment, the action spectrum was formed from the photon density which elicited the half-saturation constant (X_{50} or ED_{50}) of the percent control-adjusted melatonin suppression for each of the eight wavelengths. The half-saturation constants were derived from the eight univariant fluence-response curves shown in **Fig. 9** and the one estimated half-saturation constant from the data shown in **Fig. 10**. The relative quantum sensitivity from each group of subjects was plotted in **Fig.11** (quanta/wavelength) to illustrate the resultant action spectra for human melatonin suppression. When the data were aligned to the best-fit template for vitamin A₁-retinaldehyde photopigments, this action spectrum predicted a peak spectral sensitivity (λ_{max}) of 464 nm. There was a strong coefficient of correlation between the data and this fitted opsin nomogram ($R^2=0.91$).

Comparison of action spectra

The action spectrum for the photoreceptor system which provides input to the pineal gland appears to be distinct from the action spectra for the classical human

visual photoreceptor systems. To illustrate this, the maximal spectral absorbencies and long wavelength limbs of the human rod and cone photoreceptors that support vision (Stockman and Sharpe, 1999) are illustrated in Figure 8 along with the maximal spectral absorbence and long wavelength limb of the melatonin action spectrum. The shaded area around the melatonin action spectrum illustrates $\pm$ SD for this function.

Discussion of action spectra

The action spectrum presented here is based on univariant fluence-response curves for melatonin suppression by eight monochromatic light wavelengths in healthy subjects. These data fit a vitamin A₁ opsin template with 446–477 nm providing the strongest circadian input for melatonin regulation. These results suggest a novel photopigment in the human eye may be primarily responsible for melatonin regulation and may be distinct from the individual rod and cone photoreceptors for vision.

In developing a fluence-response curve, a complete within-subjects experimental design produces the most reliable results. When subjects are studied over a two to four month period, however, lack of stability in the subjects' circadian entrainment can introduce variability in light-induced melatonin suppression. This study accepted only volunteers who reported regular bed and wake times and their melatonin rhythms appeared to have been stable during the course of the study. As shown in the 2:00 AM melatonin values (Fig. 6), there were no significant differences between sets of pre-exposure values indicating that baseline melatonin levels were consistent across the different study nights. This phenomenon has been documented for the 505 nm fluence-response group as well as in other similarly controlled studies (Brainard et al., 1997; 2000; 2001; Wang et al., 1998). This within-subject stability of the melatonin rhythm over time has been frequently confirmed in the literature (Waldhauser and Dietzel, 1985; Arendt, 1988; 1998).

The data from each wavelength studied fit a univariant four parameter sigmoidal curve with a high coefficient of correlation. The univariance of these curves is consistent with, but does not prove, the hypothesis that melatonin

BRA01-NP001

PATENT

suppression is modulated by a single photoreceptor type. Previous studies with animals and humans have illustrated similar fluence-response relationships for melatonin suppression and other circadian responses with monochromatic and broad spectrum light (Brainard et al., 1983; 1988; Podolin et al., 1987; McIntyre et al., 1989; Nelson and Takahashi, 1991; Zeitzer et al., 2000; Dkhissi-Benyahya et al., 2000). The initial attempts to define circadian and neuroendocrine responses to photons of different wavelength began with polychromatic action spectra which tested single irradiances of broader light bandwidths in various rodent species. These polychromatic action spectra were reasonably consistent in indicating that the spectral region between 450-550 nm provides the strongest stimulation of circadian and neuroendocrine responses in rodents (for review: Brainard et al., 1999). Analytic action spectra, based on sets of fluence-response curves at different monochromatic wavelengths, are superior for identifying photoreceptors that mediate photobiological responses (Lipson, 1994; Coohill, 1999).

There are four analytic action spectra on circadian and neuroendocrine regulation in hamsters, rats and mice (Takahashi et al., 1984; Bronstein et al., 1987; Provencio and Foster, 1995; Yoshimura and Ebihara, 1996). Data from these action spectra have been fitted to spectral sensitivity curves for retinal-based visual photopigments. This curve fitting is predicated on the assumption that a retinal-based molecule transduces light stimuli for circadian regulation, and allows the prediction of the shape of the photopigment absorption spectrum as well as its peak sensitivity (I_{max}). Across these studies which employed different circadian endpoints, the predicted I_{max} ranges from 480-511 nm and is surrounded by a broad region of high sensitivity. From these results, different photopigments have been suggested to be responsible for circadian regulation, including rhodopsin, a rhodopsin-like molecule, a middle wavelength cone photopigment, or an ultraviolet cone photopigment.

It is commonly believed that the photopic visual system has a peak wavelength sensitivity around 555 nm (Rodieck, 1998). Many investigators have hypothesized that the photopic visual system mediates circadian and neuroendocrine responses, since this part of the visual system is responsive to "bright" daytime levels of illumination. Previous data (Brainard et al., 2001) and those presented above do not support this view. The results clearly demonstrate that 555 nm is significantly weaker in suppressing melatonin compared to an equal photon density of 460 nm. Thus, the

BRA01-NP001

PATENT

photopic system is not likely to be the primary input for circadian regulation. Demonstrating that the photopic visual system is not the principal phototransducer for melatonin regulation does not preclude it from having any role in circadian input.

5 Indeed, recent studies suggest that visual cones may be involved in circadian regulation. Recordings from SCN neurons in rats indicate that the visual rods and cones provide input to cells of the rat SCN (Aggelopoulos and Meissl, 2000). Similarly, a human phase-shifting study suggests that, under some circumstances, the visual long wavelength-sensitive cone may also mediate circadian vision in humans

10 (Zeitzer et al., 1997).

The data presented here do not support the view that any of the known visual photoreceptors provide the primary input for melatonin regulation. **Fig. 10** shows that none of the action spectra for individual visual photoreceptor systems match the action spectrum for melatonin suppression. If the photoreceptors that mediate vision

15 in humans are not the primary photoreceptors for circadian regulation, what are the alternative candidates? Recent studies with various vertebrate species have identified several new molecules which may serve as circadian photopigments. These putative photopigments include both opsin-based molecules such as vertebrate ancient (VA) opsin (Soni and Foster, 1997), melanopsin (Provencio et al., 1998), and peropsin (Sun et al., 1997), as well as non-opsin molecules like biliverdin (Oren, 1996) and

20 cryptochrome (Miyamoto and Sancar, 1998). Among these new photopigments, only melanopsin has been specifically localized to the human neural retina (Provencio et al., 2000) and cryptochrome has been localized to the mouse neural retina (Miyamoto and Sancar, 1998). Cryptochromes have been studied extensively as circadian photoreceptors in plants and insects (Ahmad and Cashmore, 1993; Stanewsky et al.,

25 1998), and have been proposed as circadian photoreceptors in mammals (Miyamoto and Sancar, 1998; Thresher et al., 1998). The contention that cryptochromes serve as circadian photoreceptors in humans or other mammals, however, remains controversial (van der Horst et al., 1999; Griffin et al., 1999; von Schantz et al.,

30 2000).

The action spectrum presented here matches a vitamin A₁-retinaldehyde photopigment template which supports the hypothesis that one of the new opsin photopigment candidates provides primary photic input for melatonin regulation in humans. The molecular identification of candidate opsin or non-opsin photoreceptors

BRA01-NP001

PATENT

and their localization in the retina and/or neural components of the circadian system make them well-suited to act as circadian phototransducers.

Are the effects of light on melatonin suppression relevant to general circadian regulation? Studies have shown that hamsters have a higher intensity threshold for light-induced phase-shifts of wheel running rhythms than for melatonin suppression (Nelson and Takahashi, 1991). Recently, however, a study on humans showed that the 50% response sensitivity for circadian phase-shifting (119 lux) was only slightly higher than that for melatonin suppression (106 lux) with white light (Zeitzer et al., 2000). It is possible that there are separate photoreceptors for mediating circadian entrainment versus acute suppression of melatonin. It is reasonable, however, to conclude that a variety of non-visual effects of light such as melatonin suppression, entrainment of circadian rhythms, and possibly some clinical responses to light are mediated by a shared photoreceptor system.

In general, relatively high light illuminances ranging from 2,500 to 12,000 lux are used for treating winter depression, selected sleep disorders and circadian disruption (Wetterberg, 1993; Lam, 1998). Although these light levels are therapeutically effective, some patients complain that they produce side effects of visual glare, visual fatigue, photophobia, ocular discomfort, and headache. Determining the action spectrum for circadian regulation can lead to improvements in light therapy. Total illuminances for treating a given disorder can be reduced as the wavelength emissions of the therapeutic equipment are optimized.

Modern industrialized societies employ light extensively in homes, schools, work places and public facilities to support visual performance, visual comfort, and aesthetic appreciation within the environment. Since light is also a powerful regulator of the human circadian system, future lighting strategies will need to provide illumination for human visual responses as well as homeostatic responses. The action spectrum presented here suggests that there are separate photoreceptors for visual and circadian responses to light in humans. Hence, new approaches to architectural lighting may be needed to optimally stimulate both the visual and circadian systems.

In conclusion, this study characterizes the wavelength sensitivity of the ocular photoreceptor system for regulating the human pineal gland by establishing an action spectrum for light-induced melatonin suppression. The results identify 446-477 nm portion of the spectrum as the most potent wavelengths providing circadian input for

BRA01-NP001**PATENT**

regulating melatonin secretion. These data suggest that the primary photoreceptor system for melatonin suppression is distinct from the rod and cone photoreceptors for vision. Finally, this action spectrum suggests that there is a novel retinaldehyde photopigment which mediates human circadian photoreception. These findings open the door for optimizing the utilization of light in both therapeutic and architectural applications.

5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626

BRA01-NP001

PATENT

REFERENCES

Aggelopoulos NC, Meissl H (2000) Responses of neurones of the rat suprachiasmatic nucleus to retinal illumination under photopic and scotopic conditions. J Physiol 523:211-222.

Ahmad M, Cashmore AR (1993) HY4 gene of *A. thaliana* encodes a protein with characteristics of a blue-light photoreceptor. Nature 366:162-166.

Arendt J (1988) Melatonin [Review]. Clin Endocrinol 29:205-229.

Arendt J (1998) Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod 3:13-22.

Boettner EA, Wolter JR (1962) Transmission of the ocular media. Invest Ophthalmol Vis Sci 1:776-783.

Boivin DB, JF Duffy, RE Kronauer, CA Czeisler (1996) Dose-response relationships for resetting of human circadian clock by light. Nature 379: 540-542.

Brainard GC, Richardson BA, King TS, Matthews SA, Reiter RJ (1983) The suppression of pineal melatonin content and N-acetyltransferase activity by different light irradiances in the Syrian hamster: a dose-response relationship. Endocrinology 113:293-296.

Brainard GC, Lewy AJ, Menaker M, Miller LS, Fredrickson RH, Weleber RG, Cassone V, Hudson D (1988) Dose-response relationship between light irradiance and the suppression of melatonin in human volunteers. Brain Res 454:212-218.

Brainard GC, Rollag MD, Hanifin JP (1997) Photic regulation of melatonin in humans: ocular and neural signal transduction. J Biol Rhythms 12:537-546.

BRA01-NP001

PATENT

Brainard GC, Greeson JM, Hanifin JP (1999) Action spectra for circadian and neuroendocrine regulation in mammals. In: Measurements of Optical Radiation Hazards (Matthes R, Sliney D, Didomenico S, Murray P, Phillips R, Wengraitis S, eds), pp 131-142. Munchen, Germany: ICNIRP.

Brainard GC, Rollag MD, Hanifin JP, van den Beld G, Sanford B (2000) The effect of polarized versus non-polarized light on melatonin regulation in humans. Photochem Photobiol 71:766-770.

Brainard GC, Hanifin JP, Rollag MD, Greeson J, Byrne B, Glickman G, Gerner E, Sanford B (2001) Human melatonin regulation is not mediated by the three cone photopic visual system. J Clin Endocrinol Metab 86:433-436.

Bronstein DM, Jacobs GH, Haak KA, Neitz J, Lytle LD (1987) Action spectrum of the retinal mechanism mediating nocturnal light-induced suppression of rat pineal gland N-acetyltransferase. Brain Res 406:352-356.

Coochill TP (1991) Action spectra again? Photochem Photobiol 54:859-870.

Coochill TP (1999) Photobiological action spectra- what do they mean? In: Measurements of Optical Radiation Hazards (Matthes R, Sliney D, Didomenico S, Murray P, Phillips R, Wengraitis S, eds), pp 27-39. Munchen, Germany: ICNIRP.

Czeisler CA, Shanahan TL, Klerman EB, Martens H, Brotman DJ, Emens JS, Klein T, Rizzo JF, III (1995) Suppression of melatonin secretion in some blind patients by exposure to bright light. N Engl J Med 332:6-11.

Czeisler CA, Allan JS, Strogatz SH, Ronda JM, Sanchez R, Rios CD, Freitag WO, Richardson GS, Kronauer RE (1986) Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science 233: 667-671.

Davis SE, Munson PJ, Jaffe ML, Rodbard D (1980) Radioimmunoassay data processing with a small programmable calculator. Journal of Immunoassay 1:15-25.

BRA01-NP001

PATENT

Dkhissi-Benyahya O, Sicard B, Cooper HM (2000) Effects of irradiance and stimulus duration on early gene expression (*fos*) in the suprachiasmatic nucleus: temporal summation and reciprocity. *J Neurosci* 20:7790-7797.

5

Foster RG, Provencio I, Hudson D, Fiske S, DeGrip W, Menaker M (1991) Circadian photoreception in the retinally degenerate mouse (*rd/rd*). *J Comp Physiol [A]* 169:39-50.

10

Freedman MS, Lucas RJ, Soni B, von Schantz M, Munoz M, David-Gray Z, Foster RG (1999) Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors. *Science* 284:502-504.

15

Gaddy JR, Rollag MD, Brainard GC (1993) Pupil size regulation of threshold of light-induced melatonin suppression. *J Clin Endocrinol Metab* 77:1398-1401.

20

Goto M, Ebihara S 1990 The influence of different light intensities on pineal melatonin content in the retinal degenerate C3H mouse and the normal CBA mouse. *Neurosci Lett*. 108:267-272.

Griffin EA, Staknis D, Weitz CJ (1999) Light-independent role of *Cry1* and *Cry2* in the mammalian circadian clock. *Science* 286:768-771.

25

Klein DC, Moore RY, Reppert SM (1991) *Suprachiasmatic Nucleus: The Mind's Clock*. Oxford: Oxford University Press.

Klein DC, Weller JL (1972) Rapid light-induced decrease in pineal serotonin N-acetyltransferase activity. *Science* 177:532-533.

30

Lam RW (1998) *Seasonal Affective Disorder and Beyond: Light Treatment for SAD and Non-SAD Disorders*. Washington, D.C.: American Psychiatric Press.

BRA01-NP001

PATENT

Lerman S (1987) Chemical and physical properties of the normal and aging lens: Spectroscopic (UV, fluorescence, phosphorescence, and NMR) analyses. *Am J Opt Physiol Optics* 64:11-22.

5

Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP (1980) Light suppresses melatonin secretion in humans. *Science* 210:1267-1269.

10

Lipson ED (1994) Action spectroscopy: methodology. In: *Organic Photochemistry and Photobiology* (Horspool WM and Song P-S, eds), pp 1257-1266. New York: CRC Press.

15

Lucas RJ, Foster RG (1999) Neither functional rod photoreceptors nor rod or cone outer segments are required for the photic inhibition of pineal melatonin. *Endocrinology* 140:1520-1524.

20

MacNichol EF, Levine JS, Mansfield RJW, Lipetz LE, Collins BA (1983) Microspectrophotometry of visual pigments in primate photoreceptors. In: *Colour Vision* (Mollon JD and Sharpe LT, eds), pp 14-38. Cambridge, England: Academic Press.

25

McIntyre IM, Norman TR, Burrows GD, Armstrong SM (1989) Human melatonin suppression by light is intensity dependent. *J Pineal Res* 6:149-156.

30

Miyamoto Y, Sancar A (1998) Vitamin B2-based blue-light photoreceptors in the retinohypothalamic tract as the photoactive pigments for setting the circadian clock in mammals. *Proc Natl Acad Sci U S A* 95:6097-6102.

Moore RY (1983) Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. *Federation Proceedings* 42:2783-2789.

Moore RY, Lenn NJ (1972) A retinohypothalamic projection in the rat. *J Comp Neurol* 146:1-14.

BRA01-NP001

PATENT

Morin LP (1994) The circadian visual system. Brain Res Brain Res Rev 19:102-127.

5 Nelson DE, Takahashi JS (1991) Comparison of visual sensitivity for suppression of pineal melatonin and circadian phase-shifting in the golden hamster. Brain Res 554:272-277.

Oren DA (1996) Humoral phototransduction: blood is a messenger. The Neuroscientist 2:207-210.

10 Partridge JC, De Grip WJ (1991) A new template for rhodopsin (vitamin A1 based) visual pigments. Vision Res 31:619-630.

15 Pevet P, Heth G, Hiam A, Nevo E (1984) Photoperiod perception in the blind mole rat (*Spalax ehrenbergi*, Nehring): involvement of the Harderian gland, atrophied eyes, and melatonin. J Exp Zool 232:41-50.

20 Podolin PC, Rollag MD, Brainard GC (1987) The suppression of nocturnal pineal melatonin in the Syrian hamster: dose-response curves at 500 nm and 360 nm. Endocrinology 121:266-270.

Provencio I, Foster RG (1995) Circadian rhythms in mice can be regulated by photoreceptors with cone-like characteristics. Brain Res 694:183-190.

25 Provencio I, Jiang G, De Grip WJ, Hayes WP, Rollag MD (1998) Melanopsin: an opsin in melanophores, brain, and eye. Proc Natl Acad Sci U S A 95:340-345.

Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD (2000) A novel human opsin in the inner retina. J Neurosci 20:600-605.

30 Reiter RJ (1991) Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12:151-180.

BRA01-NP001

PATENT

Rodieck RW (1998) *The First Steps in Seeing*, Sunderland, Massachusetts: Sinauer Associates, Inc.

5 Rollag MD, Niswender GD (1976) Radioimmunoassay of serum concentrations of melatonin in sheep exposed to different lighting regimens. *Endocrinology* 98:482-489.

10 Ruberg FL, Skene DJ, Hanifin JP, Rollag MD, English J, Arendt J, Brainard GC (1996) Melatonin regulation in humans with color vision deficiencies. *J Clin Endocrinol Metab* 81:2980-2985.

15 Schwartz WJ, Busis NA, Hedley-Whyte ET (1986) A discrete lesion of ventral hypothalamus and optic chiasm that disturbed the daily temperature rhythm. *J Neurol* 233:1-4.

Smith KC (1989) *The Science of Photobiology*. New York: Plenum Press.

20 Soni BG, Foster RG (1997) A novel and ancient vertebrate opsin. *FEBS Lett* 406:279-283.

25 Stanewsky R, Kaneko M, Emery P, Beretta B, Wager-Smith K, Kay SA, Rosbash M, Hall JC (1998) The cry mutation identifies cryptochrome as a circadian photoreceptor in drosophila. *Cell* 95:681-692.

Stockman A, Sharpe LT (1999) Cone spectral sensitivities and color matching. In: *Color Vision: From Genes to Perception* (Gegenfurtner KR and Sharpe LT, eds), pp 53-87. Cambridge, United Kingdom: Cambridge University Press.

30 Sun H, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J (1997) Peropsin, a novel visual pigment-like protein located in the apical microvilli of the retinal pigment epithelium. *Proc Natl Acad Sci U S A* 94:9893-9898.

BRA01-NP001

PATENT

Takahashi JS, DeCoursey PJ, Bauman L, Menaker M (1984) Spectral sensitivity of a novel photoreceptive system mediating entrainment of mammalian circadian rhythms. *Nature* 308:186-188.

5

Thresher RJ, Vitaterna MH, Miyamoto Y, Kazantsev A, Hsu DS, Petit C, Selby CP, Dawut L, Smithies O, Takahashi JS, Sancar A (1998) Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses. *Science* 282:1490-1494.

10

van der Horst GTJ, Muijtjens M, Kobayashi K, Takano R, Kanno S, Takao M, de Wit J, Verkerk A, Eker APM, van Leenen D, Buijs R, Bootsma D, Hoeijmakers JHJ, Yasui A (1999) Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms. *Nature* 398:627-630.

15

von Schantz M, Provencio I, Foster RG (2000) Recent developments in circadian photoreception: more than meets the eye. *Invest Ophthalmol Vis Sci* 41:1605-1607.

20

Waldhauser F, Dietzel M (1985) Daily and annual rhythms in human melatonin secretion: role in puberty control. *Ann N Y Acad Sci* 453:205-214.

Wang JY, Hanifin JP, Rollag MD, Brainard GC (1999) Ocular regulation of the human pineal gland: the significance of total retinal exposure for melatonin suppression. In: *Biologic Effects of Light 1998* (Holick M and Jung EG, eds), pp 367-374. Boston, Massachusetts: Kluwer Academic Publishers.

25

Webb SM, Champney TH, Lewinski AK, Reiter RJ (1985) Photoreceptor damage and eye pigmentation: influence on the sensitivity of rat pineal N-acetyltransferase activity and melatonin levels to light at night. *Neuroendocrinology* 40:205-209.

30

Wehr TA (1991) The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). *J Clin Endocrinol Metab* 73:1276-1280.

Wetterberg L (1993) *Light and Biological Rhythms in Man*. Stockholm: Pergamon Press.

BRA01-NP001**PATENT**

Yoshimura T, Ebihara S (1996) Spectral sensitivity of photoreceptors mediating phase-shifts of circadian rhythms in retinally degenerate CBA/J (*rd/rd*) and normal CBA/N (+/+) mice. J Comp Physiol [A] 178:797-802.

5

Zeitzer JM, Kronauer RE, Czeisler CA (1997) Photopic transduction implicated in human circadian entrainment. Neurosci Lett 232:135-138.

10

Zeitzer JM, Dijk D-J, Kronauer RE, Brown EN, Czeisler CA (2000) Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol 526:695-702.

15

1995 Special Issue: Task force report on light treatment for sleep disorder J Biol Rhythms 10: 99-176.

BRA01-NP001

PATENT

WHAT IS CLAIMED IS:

1. A method of treating or preventing a light responsive disorder in a mammal,
5 comprising administration of a therapeutically effective amount of light to said
mammal, said light being generated by a light system, wherein said light system emits
a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine
system of said mammal, said balance of wavelengths having a peak sensitivity
ranging from 425 –505 nm.

10 2. The method of **Claim 1**, wherein said light responsive disorder is at least one
of the group of seasonal affective disorder (SAD), a sleep disorder, circadian
disruption, eating disorders, menstrual cycle disorders, non-specific alerting or
performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

15 3. A method of treating a light responsive disorder in a mammal, comprising
administration of a therapeutically effective amount of light to said mammal, said
light being generated by a light system, wherein said light system excludes emission
of a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine
20 system of said mammal, said balance of wavelengths having a peak sensitivity
ranging from 425 –505 nm.

25 4. The method of **Claim 3**, wherein said light responsive disorder is at least one
of the group of seasonal affective disorder (SAD), a sleep disorder, circadian
disruption, eating disorders, menstrual cycle disorders, non-specific alerting or
performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

30 5. A light system, comprising at least one light source, said light source emitting
a balance of wavelengths to stimulate a mammalian circadian, photoneural, or
neuroendocrine system, said balance of wavelengths having a peak sensitivity ranging
from 425 –505 nm.

BRA01-NP001

PATENT

6. A light system, comprising at least one light source, said light source excluding emission of a balance of wavelengths to stimulate a mammalian circadian, photoneural, or neuroendocrine system, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

7. A transparent composition, comprising at least one light filtering component, said light filtering component specifically transmitting a balance of wavelengths for stimulating a mammalian circadian, photoneural, or neuroendocrine system, said balance of wavelengths having a peak transmittance ranging from 425 –505 nm.

8. A translucent composition, comprising at least one light filtering component, said light filtering component specifically transmitting a balance of wavelengths for stimulating a mammalian circadian, photoneural, or neuroendocrine system, said balance of wavelengths having a peak transmittance ranging from 425 –505 nm.

9. A transparent composition, comprising at least one light filtering component, said light filtering component specifically blocking a balance of wavelengths for stimulating a mammalian circadian, photoneural, or neuroendocrine system, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

10. A translucent composition, comprising at least one light filtering component, said light filtering component specifically blocking a balance of wavelengths for stimulating a mammalian circadian, photoneural, or neuroendocrine system, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

11. A method of treating a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system comprises at least one light source and at least one transparent material component, said light source emitting light through said transparent material component, said transparent material component comprising at least one light filtering component, said light filtering component specifically transmitting a balance of wavelengths to stimulate a circadian,

BRA01-NP001

PATENT

photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

5 **12.** The method of **Claim 11**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

10 **13.** A method of treating a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system comprises at least one light source and at least one translucent material component, said light source emitting light through said translucent material component, said translucent material
15 component comprising at least one light filtering component, said light filtering component specifically transmitting a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

20 **14.** The method of **Claim 13**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

25 **15.** A method of treating a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system comprises at least one light source and at least one transparent material component, said light source emitting light through said transparent material component, said transparent material
30 component comprising at least one light filtering component, said light filtering component specifically blocking a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

BRA01-NP001

PATENT

16. The method of **Claim 15**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

17. A method of treating a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system comprises at least one light source and at least one translucent material component, said light source emitting light through said translucent material component, said translucent material component comprising at least one light filtering component, said light filtering component specifically blocking a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –5055 nm.

18. The method of **Claim 17**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

19. A light meter system for quantifying light which stimulates a mammalian circadian, photoneural, or neuroendocrine system under normal conditions or which provides light therapy, said light meter system comprising at least one light metering device configured to match wavelength sensitivity of mammalian photoreceptors for circadian and neuroendocrine regulation, said wavelength having a peak sensitivity ranging from 425-505 nm.

BRA01-NP001

PATENT

ABSTRACT

5 The present invention involves a light system for stimulating or regulating
neuroendocrine, circadian, and photoneural systems in mammals based upon the
discovery of peak sensitivity ranging from 425-505 nm; a light meter system for
quantifying light which stimulates or regulates mammalian circadian, photoneural,
and neuroendocrine systems. The present invention also relates to translucent and
transparent materials, and lamps or other light sources with or without filters capable
10 of stimulating or regulating neuroendocrine, circadian, and photoneural systems in
mammals. Additionally, the present invention involves treatment of mammals with a
wide variety of disorders or deficits, including light responsive disorders, eating
disorders, menstrual cycle disorders, non-specific alerting and performance deficits,
hormone-sensitive cancers, and cardiovascular disorders.

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

1/12




Fig. 1

2/12




Fig. 2

3/12




Fig. 3

4/12

2025-03-04 15:50:00

Plasma Melatonin
% Change Control-Adjusted




Fig. 4

5/12




Fig. 5

6/12




Fig. 6

7/12




Fig. 7

8/12




Fig. 8

9/12




Fig. 9

10/12




Fig. 10

11/12




Fig. 11

12/12




Fig. 12

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☒ The attached application, or
☐ Application No. _____, filed on _____,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/ we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable; and

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: George Brainard

Signature:  Citizen of: United States

Inventor two: _____

Signature: _____ Citizen of: _____

Inventor three: _____

Signature: _____ Citizen of: _____

Inventor four: _____

Signature: _____ Citizen of: _____

☐ Additional inventors are being named on _____ additional form(s) attached hereto.

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Thomas Jefferson UniversityApplication No./Patent No.: _____ Filed/Issue Date: May 10, 2001Entitled: Photoreceptor System For Melatonin Regulation And Photo Therapy

Thomas Jefferson University, a University

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____%

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

10 May 2001

Date

Alan B. Kelly, Esq.

(Typed or printed name)

Signature

University Counsel and Senior Officer

Title

J1036 U.S. PTO

09/853428

09/10/01

Class	Subclass	ISSUE CLASSIFICATION

PATENT NUMBER

U.S. UTILITY Patent Application

O.I.P.E.	PATENT DATE
MR CH3 SCANNED O.A. A.G.	

APPLICATION NO. 09/853428	CONT/PRIOR D	CLASS 514 607	SUBCLASS 028	ART UNIT 3739	EXAMINER Gibson
------------------------------	-----------------	---------------------	-----------------	------------------	--------------------

APPLICANTS

George Brainard

TITLE

Photoreceptor system for melatonin regulation and phototherapy

PTO-2040
12/89

ISSUING CLASSIFICATION

ORIGINAL		CROSS REFERENCE(S)					
CLASS	SUBCLASS	CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)				
INTERNATIONAL CLASSIFICATION							

☐ Continued on Issue Slip Inside File Jacket

☐ TERMINAL DISCLAIMER	DRAWINGS			CLAIMS ALLOWED	
	Sheets Drwg.	Figs. Drwg.	Print Ftg.	Total Claims	Print Claim for O.G.
☐ The term of this patent subsequent to _____ (date) has been disclaimed.				NOTICE OF ALLOWANCE MAILED	
☐ The term of this patent shall not extend beyond the expiration date of U.S. Patent. No. _____					
				ISSUE FEE	
				Amount Due	Date Paid
☐ The terminal _____ months of this patent have been disclaimed.				ISSUE BATCH NUMBER	
WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 398. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.					

Form PTO-438A
(Rev. 8/99)FILED WITH: ☐ DISK (CRF) ☐ FICHE ☐ CD-ROM
(Attached in pocket on right inside flap)

BEST AVAILABLE COPY

POSITION	INITIALS	ID NO.	DATE
FEE DETERMINATION	16		05-15-01
O.I.P.E. CLASSIFIER		8	6-1-01
FORMALITY REVIEW	F 1	926	07-09-01
RESPONSE FORMALITY REVIEW			

INDEX OF CLAIMS

✓ Rejected N Non-elected
 = Allowed I Interference
 - (Through numeral)... Canceled A Appeal
 + Restricted O Objected

Claim	Final	Original	Date
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			

Claim	Final	Original	Date
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			
61			
62			
63			
64			
65			
66			
67			
68			
69			
70			
71			
72			
73			
74			
75			
76			
77			
78			
79			
80			
81			
82			
83			
84			
85			
86			
87			
88			
89			
90			
91			
92			
93			
94			
95			
96			
97			
98			
99			
100			

Claim	Final	Original	Date
101			
102			
103			
104			
105			
106			
107			
108			
109			
110			
111			
112			
113			
114			
115			
116			
117			
118			
119			
120			
121			
122			
123			
124			
125			
126			
127			
128			
129			
130			
131			
132			
133			
134			
135			
136			
137			
138			
139			
140			
141			
142			
143			
144			
145			
146			
147			
148			
149			
150			

BEST AVAILABLE COPY

If more than 150 claims or 10 actions
staple additional sheet here

(LEFT INSIDE)

05-14-01

A

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0851-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. **BRA01-NP002**

First Inventor **BRAINARD, George**

Title **Photoreceptor System For Melatonin Regulation and Phototherapy**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Express Mail Label No. **EJ464028033US**

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages **49**]
(preferred arrangement set forth below)
- Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **12**]5. Oath or Declaration [Total Pages **1**]

- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
- i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).

6. ☒ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ paper
- c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☒ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other: _____

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Prior application information:

Examiner _____

Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

24358

(insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

Fax

Name (Print/Type)

Clifford Kent Weber

Registration No. (Attorney/Agent) 42,215

Signature

Clifford Kent Weber

Date

May 10, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

05/10/01

J1036 U.S. PTO

J1036 U.S. PTO

09/853428

05/10/01

05/10/01
Jc961 U.S. PTO

PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$)**755.00**

Complete if Known

Application Number	
Filing Date	May 10, 2001
First Named Inventor	BRAINARD, George
Examiner Name	
Group Art Unit	
Attorney Docket No.	BRA01-NP002

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **50-0491**
Deposit Account Name **Thomas Jefferson University**

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☒ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	710	201	355	Utility filing fee	\$355.00
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$)**355.00**

2. EXTRA CLAIM FEES

Total Claims **19** Extra Claims **-20** = 1** Fee from below **\$9.00** Fee Paid **\$0.00**
Independent Claims **13** **-3** = 10** **\$40.00** **\$400.00**
Multiple Dependent

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)**400.00**

*or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**0.00**

SUBMITTED BY

Name (Print/Type) **Clifford Kent Weber**

Signature _____

Registration No. (Attorney/Agent) **42,215**

Complete (if applicable)

Telephone **(215) 503-0757**

Date **May 10, 2001**

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.: BRA01-NP002

TITLE: Photoreceptor System For Melatonin Regulation And Phototherapy

INVENTOR(S): BRAINARD, George

"Express Mail" Label No. EJ464028033US

Date of Deposit – May 10, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

By Clifford Kent Weber

Typed Name: Clifford Kent Weber

Box Patent Application

Commissioner of Patents & Trademarks
Washington, DC 20231

0
1
2
3
4
5
6
7
8
9
10
11
12

1/12




Fig. 1

2/12




Fig. 2

3/12




Fig. 3

4/12




Fig. 4

5/12

TOP SECRET




Fig. 5

Figure 1: Schematic representation of the experimental design. The diagram shows a sequence of steps: 1. Selection of 1000 subjects, 2. Random assignment to 500 pairs, 3. Presentation of a stimulus (a pair of faces), 4. Decision (Yes/No), 5. Feedback (Correct/Incorrect), 6. End of trial. The stimulus is a pair of faces, one of which is the target face. The decision is based on whether the target face is present or absent. The feedback is given after the decision. The end of trial is marked by a green bar.



Fig. 6

7/12




Fig. 7

8/12




Fig. 8

9/12




Fig. 9

10/12




Fig. 10

11/12




Fig. 11

12/12




Fig. 12

**PHOTORECEPTOR SYSTEM FOR MELATONIN REGULATION AND
PHOTOTHERAPY**

5

CROSS REFERENCE TO RELATED APPLICATIONS

10 This application claims priority under 35 U.S.C. § 119 based upon U.S. Provisional Patent Application No. 60/203,308 filed May 10, 2000 and upon U.S. Provisional Patent Application No.60/228,493 filed August 28, 2000.

GOVERNMENT RIGHTS IN THE INVENTION

15

This invention was made with government support under grants from NIH RO1NS36590 awarded by the National Institutes of Health.; NSBIR/NASA HPF.002.08 (to GCB) awarded by the National Space Biology Research Institute in cooperation with the National Aeronautics and Space Administration; NSF IBN9809916 awarded by the National Science Foundation; and DOD R070HY (to MDR) awarded by the Department of Defense. The government has certain rights in the invention.

25

FIELD OF THE INVENTION

30

The present invention generally relates to the fields of neurology, neuroscience, and endocrinology and to light systems, light meters, lamps, filters, transparent and translucent materials, and methods of treating a variety of mammalian disorders and, more particularly to a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm; a light meter system for quantifying light which stimulates mammalian circadian, photoneural, and

BRA01-NP

PATENT

neuroendocrine systems; translucent and transparent materials, and lamps or other light sources with or without filters stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals; and treatment of mammals with a wide variety of disorders or deficits, including light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficit, hormone-sensitive cancers, and cardiovascular disorders.

BACKGROUND OF THE INVENTION

Light is the primary stimulus for regulating circadian rhythms, seasonal cycles, and neuroendocrine responses in many species including humans (Klein et al., 1991; Wehr, 1991). Further, clinical studies have demonstrated that light therapy is effective for treating selected affective disorders, sleep problems, and circadian disruptions (Wetterberg, 1993; Lam, 1998). Previously, the ocular photoreceptors which transduce light stimuli for circadian regulation and the clinical benefits of light therapy have been unknown.

Nonetheless, scientists have been deeply involved in elucidating the physiologic and functional anatomic features associated with light and vision. In fact, the underlying neuroanatomy and neurophysiology which mediate vision have been studied extensively over the past two centuries. More recently, the retinohypothalamic tract (RHT), a distinct neural pathway which mediates circadian regulation by environmental light, has been shown to project from the retina to the suprachiasmatic nuclei (SCN) in the hypothalamus. (Moore RY, Lenn NJ. A retinohypothalamic projection in the rat. *J Comp Neurol* 146:1-14, 1972; Moore RY (1983) Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. *Federation Proceedings* 42:2783-2789; Klein DC, Moore RY, Reppert SM, eds. *Suprachiasmatic Nucleus: The Mind's Clock*. Oxford: Oxford University Press, 5-456, 1991; Morin LP (1994) The circadian visual system. *Brain Res Brain Res Rev* 19:102-127). By this pathway, light and dark cycles are perceived through the mammalian eyes, entrain SCN neural activity and, in turn, entrain the rhythmic secretion of melatonin from the pineal gland. In virtually all

BRA01-NP001

PATENT

species, melatonin secretion is high during the night and low during the day (Reiter, 1991; Arendt, 1998).

In addition to entraining pineal rhythms, light exposure can acutely suppress melatonin secretion (Rollag and Niswender, 1976; Lewy et al., 1980). A well-defined multisynaptic neural pathway extends from the SCN to the pineal gland, which transmits information about light and circadian time for entraining the rhythmic production and secretion of the hormone melatonin. (Moore RY, Lenn NJ. *J Comp Neurol* 146:1-14, 1972; Klein DC et al., eds. *Suprachiasmatic Nucleus: The Mind's Clock*. 5-456, 1991; Schwartz WJ, Busis NA, Hedley-Whyte ET. A discrete lesion of ventral hypothalamus and optic chiasm that disturbed the daily temperature rhythm. *J Neurol* 233:1-4, 1986; Arendt J. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. *Rev Reprod* 3: 13-22, 1998). In addition to synchronizing pineal indolamine circadian rhythms, ocular exposure to light during the night can acutely suppress melatonin synthesis and secretion (Klein DC, Weller JL (1972) Rapid light-induced decrease in pineal serotonin N-acetyltransferase activity. *Science* 177:532-533; Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP (1980) Light suppresses melatonin secretion in humans. *Science* 210:1267-1269). Light-induced melatonin suppression is a well-defined, broadly used marker for photic input to the RHT and SCN (Klein DC, 1991; Arendt J (1998) Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. *Rev Reprod* 3:13-22; Brainard GC, Rollag MD, Hanifin JP (1997) Photic regulation of melatonin in humans: ocular and neural signal transduction. *J Biol Rhythms* 12:537-546; Lucas RJ, Foster RG (1999) Neither functional rod photoreceptors nor rod or cone outer segments are required for the photic inhibition of pineal melatonin. *Endocrinology* 140:1520-1524).

Previously, it has not been known what photoreceptors transduce light stimuli for circadian regulation. Studies on animals with hereditary or light-induced retinal degeneration have raised the possibility that neither the rods nor the cones used for vision participate in light-induced melatonin suppression, circadian locomotor phase-shifts, or photoperiodic responses (Lucas, 1999; Webb SM, Champney TH, Lewinski AK, Reiter RJ (1985) Photoreceptor damage and eye pigmentation: influence on the sensitivity of rat pineal N-acetyltransferase activity and melatonin levels to light at night. *Neuroendocrinology* 40:205-209; Goto M, Ebihara S (1990) The influence of

BRA01-NP001

PATENT

different light intensities on pineal melatonin content in the retinal degenerate C3H mouse and the normal CBA mouse. *Neurosci Lett.* 108:267-272; Foster RG, Provencio I, Hudson D, Fiske S, DeGrip W, Menaker M (1991) Circadian photoreception in the retinally degenerate mouse (*rd/rd*). *J Comp Physiol [A]* 169:39-50; Freedman MS, Lucas RJ, Soni B, von Schantz M, Munoz M, David-Gray Z, Foster RG (1999) Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors. *Science* 284:502-504). Studies using rodents with retinal degeneration suggest that neither the rods nor cones used for vision participate in light-induced melatonin suppression, circadian phase-shifts, or photoperiodic responses (Pevet et al., 1984; Webb et al., 1985; Foster et al., 1991). Furthermore, enucleation of rod-less, cone-less transgenic mice abolishes light-induced circadian phase-shifts and melatonin suppression (Lucas and Foster, 1999; Freedman et al., 1999). Recently, light-induced melatonin suppression and circadian entrainment have been demonstrated in humans with complete visual blindness (Czeisler CA, Shanahan TL, Klerman EB, Martens H, Brotman DJ, Emens JS, Klein T, Rizzo JF, III (1995) Suppression of melatonin secretion in some blind patients by exposure to bright light. *N Engl J Med* 332:6-11) and with specific color vision deficiencies. (Ruberg, 1996). The study on humans with color vision deficiencies showed that protanopic and deuteranopic subjects who lacked functioning long wavelength-sensitive cones (red, or L cones), and middle wavelength cone photoreceptors (green, or M cones), exhibited normal light-induced melatonin suppression and entrainment of the melatonin rhythm (Ruberg FL, Skene DJ, Hanifin JP, Rollag MD, English J, Arendt J, Brainard GC (1996) Melatonin regulation in humans with color vision deficiencies. *J Clin Endocrinol Metab* 81:2980-2985). Thus, by themselves, neither the red nor green cone system could be the primary input for melatonin regulation, at least in humans with color vision deficiencies. Together, the results from human and animal circadian studies on different forms of visual blindness suggest that melatonin regulation by light is controlled, at least in part, by photoreceptors which differ from the photoreceptors that mediate vision.

Recent studies with various vertebrate species have identified several new molecules which may serve as circadian photopigments. These putative photopigments include both opsin-based molecules, such as vertebrate ancient (VA)

BRA01-NP001

PATENT

opsin and melanopsin, as well as non-opsin molecules like the cryptochromes (Soni BG, Foster RG (1997) A novel and ancient vertebrate opsin. *FEBS Lett* 406:279-283; Provencio I, Jiang G, De Grip WJ, Hayes WP, Rollag MD (1998) Melanopsin: an opsin in melanophores, brain, and eye. *Proc Natl Acad Sci U S A* 95:340-345; Miyamoto Y, Sancar A (1998) Vitamin B2-based blue-light photoreceptors in the retinohypothalamic tract as the photoactive pigments for setting the circadian clock in mammals. *Proc Natl Acad Sci U S A* 95:6097-6102). Among these new photopigments, only melanopsin has been specifically localized to the human retina. (Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD (2000) A novel human opsin in the inner retina. *J Neurosci* 20:600-605). The molecular identification of these candidate photopigments and their localization in the retina and/or neural components of the circadian system make them well-suited to act as circadian phototransducers. Functional data confirming their direct role in circadian photoreception, however, have been lacking.

The present invention required determining whether or not the three cone system, which supports photopic (daytime) vision, was also the primary input for pineal melatonin suppression in humans with normal, healthy eyes. The peak wavelength sensitivity of the photopic visual system is near 555 nm. (Rodieck RW (1998) *The First Steps in Seeing*, Sunderland, Massachusetts: Sinauer Associates, Inc.). If melatonin regulation were mediated primarily by the three cone photopic visual system, then 555 nm light would be the most potent wavelength for regulating melatonin secretion.

In the present invention, data show that 505 nm is approximately four times stronger than 555 nm in suppressing melatonin. These results demonstrate that the ocular photoreceptor primarily responsible for pineal melatonin regulation in humans, is not the cone system that is believed to mediate photopic vision. This present invention involved the first test of a specific photoreceptor system for melatonin regulation in humans with healthy, intact eyes.

Developing an action spectrum is a fundamental means for determining the input physiology for the circadian system. This photobiological technique has high utility for 1) defining the relative effectiveness of photons at different wavelengths for eliciting a biological response, and 2) identifying the specific photopigment involved in that response. (Lipson, 1994; Coohill, 1999). The specific aim of the present study

was to characterize the wavelength sensitivity of the photoreceptor system responsible for providing circadian input to the human pineal gland by establishing an action spectrum for light-induced melatonin suppression. The experiments defined an action spectrum that fits a retinaldehyde opsin template and identified 446-477 nm as the most potent wavelength region for regulating melatonin. Univariate among the eight fluence-response curves suggests that a single photopigment is primarily responsible for melatonin suppression. These results suggest that there is a novel photopigment in the human eye which mediates circadian photoreception.

Light as a therapeutic stimulus

Numerous studies have shown that environmental light is the primary stimulus for regulating circadian rhythms, seasonal cycles, and neuroendocrine responses in many mammalian species including humans (Klein et al., 1991; Morin, 1994; Czeisler, 1995). During the past 20 years, studies have tested the use of light for treating fall and winter depression (Seasonal Affective Disorder or SAD), nonseasonal depression, sleep disorders, menstrual dysfunction, and eating disorders. In addition, investigators are exploring the use of light for re-entraining human circadian physiology relative to the challenge of shift work or intercontinental air travel. A Congressional report estimated that there are 20 million shift workers in the United States. (US Congress, 1991). The two most common problems associated with shift work are reduced alertness on the job and reduced sleep quality after work. In addition, shift workers have increased health problems including higher risk of cardiovascular disease and gastrointestinal distress as well as cognitive and emotional problems. Chronic desynchronization of the circadian system is cited as one of the causes for these problems. (US Congress, 1991).

Light is known to be a potent stimulus for entraining and phase-shifting circadian rhythms in many species, including humans. (Czeisler et al., 1986; Klein et al., 1991). The circadian response to light is dependent on the stimulus intensity, wavelength and time of delivery. A phase-response curve (PRC) describes light-induced shifts in rhythms relative to the circadian phase when the light is given, and PRCs to light share similarities across many species.

Working from the human PRC to light, some investigators have tested strategies of light treatment to improve circadian entrainment thereby enhancing performance, alertness, and health in shift workers. Studying simulated shift work, different groups of investigators have shown that workers had accelerated circadian re-entrainment, enhanced alertness, and improved sleep quality after treatment with bright light (2,000 lux to 12,000 lux) versus dimmer light (10 lux to 150 lux).

Light stimulation of the circadian and neuroendocrine systems

Over the last two centuries, extensive research has elucidated the neuroanatomy and neurophysiology which support the sensory capacity of vision in mammals. More recently, animal studies have demonstrated a neural pathway, named the retinohypothalamic tract (RHT), which projects from the retina into the hypothalamus. (Moore and Lenn, 1972; Klein et al., 1991). Information about light is transmitted from the retina to the hypothalamic suprachiasmatic nuclei (SCN) which are fundamental circadian oscillators that regulate daily rhythms. (Klein et al., 1991). The pathways supporting vision and circadian regulation are anatomically separate, but there may be a link between these systems by a projection from the intergeniculate leaflet to the SCN. (Morin, 1994). Although the detailed neuroanatomy of the circadian system primarily has been determined with animal studies, parallel clinical and post-mortem studies suggest that humans have a similar circadian neuroanatomy. (Schwartz et al., 1986).

The circadian system controls daily rhythms of sleep, wakefulness, body temperature, hormonal secretion, and other physiological parameters. (Klein et al., 1991; Morin, 1994; Lam, 1998). There is considerable evidence from studies on mammals that the circadian and neuroendocrine effects of light are mediated via photoreceptive physiology in the eye as opposed to photoreceptive physiology in the skin or some other part of the body. A study by Campbell and Murphy (1998), however, reported that a 3 hour bright light pulse of 13,000 lux delivered to the backs of the knees of human subjects systematically reset circadian rhythms of body temperature and melatonin. In contrast, two recent studies failed to elicit acute melatonin suppression with similar bright light exposure to the backs of the knees in

BRA01-NP001

PATENT

healthy humans and an attempt to replicate Campbell and Murphey's findings failed to demonstrate a phase-shift after light exposure to the back of the. Further work is needed to determine whether or not the eyes are the exclusive sites for circadian photoreception in humans and other mammalian species. Data suggest that the eyes are the primary (if not exclusive) site for circadian and neuroendocrine phototransduction. Although light is the principal stimulus for regulating the circadian system, other external stimuli such as sound, temperature, social cues and conditioning may also influence physiological timing functions.

Light regulation of melatonin

A well-defined neural pathway carries photic information about light extends from the SCN to the pineal gland via a multisynaptic pathway with connections being made sequentially in the paraventricular hypothalamus, the upper thoracic intermediolateral cell column, and the superior cervical ganglion. (Moore, 1983). By way of this neuroanatomy, cycles of light and dark which are perceived through the eyes entrain SCN neural activity which, in turn, entrains the rhythmic synthesis and secretion of melatonin from the pineal gland. In virtually all species including humans, high levels of melatonin are secreted during the night and low levels are secreted during the day.

In addition to entraining the melatonin circadian rhythm, light can acutely suppress melatonin secretion. Specifically, exposure of the eyes to light during the night causes a rapid decrease in the high activity of the pineal enzyme serotonin-N-acetyltransferase and subsequent inhibition of synthesis and secretion of melatonin. The acute light-induced suppression of melatonin was first observed in rats and later in humans (Klein and Weller, 1972; Lewy et al., 1980). This response has been used as a tool by the PI (GCB) and many other investigators to help determine the ocular, neural and biochemical physiology for melatonin regulation. (Klein et al., 1991; Brainard et al., 1997). In addition, seasonal changes in photoperiod length alters the duration of the elevated melatonin production. Specifically, in a number of mammalian species including humans, the duration of increased nocturnal melatonin secretion is shorter in the summer due to shortened night time periods. In summary,

many studies have shown that light stimuli are the strongest and most consistent regulators of melatonin. In addition, certain drugs can powerfully impact melatonin secretion, while other non-photic and non-pharmacologic stimuli that may modify melatonin levels include body posture and exercise.

Phototransduction and action spectrum analysis

The overall aim of the present invention is the identification of the photoreceptor(s) for applications in the areas of circadian regulation, neuroendocrine regulation, and the clinical benefits of light therapy in humans. Fundamentally, all photobiological responses are mediated by specific organic molecules that absorb photons and then undergo physical-chemical changes which, in turn, lead to broader physiological changes within the organism. This photobiological process is termed phototransduction and the organic molecules which absorb light energy to initiate photobiological responses are called photopigments. Generally, these photoactive molecules do not absorb energy equally across the electromagnetic spectrum. Each photoreceptor molecule or complex has a characteristic absorption spectrum which depends on its atomic structure. An action spectrum is one of the main tools for identifying the photopigment which initiates a photobiological response. The simplest definition of an action spectrum is the relative response of an organism to different wavelengths. (Lipson, 1994; Coohill, 1999).

Photobiologists have evolved a refined set of practices and guidelines for determining analytical action spectra which are applicable to all organisms from plants to humans. (Coohill, 1991; Lipson, 1994). Analytical action spectra are developed using two or more monochromatic light stimuli with half-peak bandwidths of 15 nm or less. Generally, these action spectra are determined by establishing a set of dose-response curves (fluence-response curves) at different wavelengths for a specific biological response. The action spectrum is then formed by plotting the reciprocal of incident photons required to produce the criterion biological response versus wavelength. This fundamental photobiological technique has high utility for 1) defining the relative effectiveness of different wavelengths for eliciting a biological response, and 2) identifying the specific photosensitive molecules involved in

biological responses.

5 *Action spectra for circadian regulation in rodents*

As in other fields of photobiology, the initial attempts to define circadian and neuroendocrine responses to wavelength began with polychromatic action spectra which tested broader bandwidths of light in various rodent species (Coohill, 1991).
 10 These polychromatic action spectra were published mainly during the early 1970's through the mid 1980's and were reasonably consistent in indicating that the spectral region between 450 nm and 550 nm provides the strongest stimulation of circadian and neuroendocrine responses in rodents (for review: Brainard et al., 1999). Analytic action spectra, however, are superior to polychromatic action spectra for identifying
 15 the photopigments that mediate photobiological responses.

In a landmark study, Takahashi and colleagues determined an analytic action spectrum for circadian wheel running behavior in Syrian hamsters (Takahashi et al., 1984). Their study established fluence-response functions for a set of monochromatic wavelengths and then formed an action spectrum from those fluence-response
 20 functions. Their action spectrum had a spectral peak (λ_{max}) around 500 nm and seemed similar in shape to the absorption spectrum for rhodopsin. Although they found these data to support the hypothesis that a rhodopsin-based photopigment and rod cells in the retina mediate circadian entrainment in hamsters, they were careful to point out that the participation of a cone mechanism could not be excluded. Since
 25 then, three other analytic action spectra have been published on circadian and neuroendocrine regulation in rodents. (Bronstein et al., 1987; Provencio and Foster, 1995; Yoshimura and Ebihara, 1996). Data from these action spectra have been fitted to spectral sensitivity curves for retinal-based visual photopigments. This curve fitting is predicated on the assumption that a retinal-based molecule transduces light
 30 stimuli for circadian regulation, and allows the prediction of the shape of the photopigment absorption spectrum as well as its peak sensitivity (λ_{max}). Across these rodent studies, the predicted λ_{max} ranges from 480 nm to 511 nm and is surrounded by a broad region of high sensitivity. From these studies, different

BRA01-NP001

PATENT

photopigments have been suggested to be responsible for circadian regulation including rhodopsin, a rhodopsin-like molecule, a middle wavelength cone photopigment, or a UV cone photopigment. Furthermore, preliminary data from other investigators working with Takahashi, showed that the action spectrum for photoperiod-dependent reproductive development response of male Siberian hamsters and light-induced phase-shifting of circadian locomotor activity has its λ_{max} in the range of 475 nm. The investigators interpret their unpublished action spectra to support the hypothesis that a short wavelength-sensitive photoreceptor mediates both functions. (Fred Turek, PhD, personal communication).

Circadian regulation in rodents with loss of cone and rod photoreceptors

It is important to note that there is considerable diversity in the cellular structure and function of the retina across mammalian species, and that in rodents the retina contains both cone and rod photoreceptors. (Rodieck, 1998). Early studies with blind mole rats and rats with destruction of retinal photoreceptors due to prolonged light exposure raised the possibility that neither the rods nor the cones used for vision participate in regulating the circadian and neuroendocrine systems. (Pevet et al., 1984; Webb et al., 1985). Despite profound loss of photoreceptors and vision, light detection for circadian and photoperiodic regulation was preserved. It remained possible, however, that a small population of surviving rods or cones could still be responsible for circadian photoreception.

Studies in mice with hereditary retinal disorders (*rd/rd* and *rds/rds*) have shown that these animals still exhibit normal light-induced melatonin suppression and circadian locomotor phase-shifts despite a nearly total loss of classical visual photoreceptors. The data support the conclusion that circadian photoreception is maintained either by 1) a very small number of rod or cone cells, or 2) an unrecognized class of retinal photoreceptors. (Foster et al., 1991; Provencio et al., 1994; Yoshimura et al., 1994). Further work with *rd* mice suggested that middle-wavelength sensitive (M-cones) and/or S-cones may be responsible for circadian photoreception. (Provencio and Foster, 1995; Yoshimura and Ebihara, 1996). Recent studies with transgenic coneless (*cl*) mice which have extensive loss of M-cones and

BRA01-NP001

PATENT

S-cones show that these mice exhibit normal sensitivity for light-induced melatonin suppression and circadian phase-shifting of locomotion. (Lucas et al., 1999; Freedman et al., 1999). Similarly, coneless, rodless mice (*rd/rd cl*) also appeared to exhibit normal sensitivity for light-induced melatonin suppression and phase-shifting of wheel-running behavior. These results indicate that rods, M-cones and S-cones are not required for circadian photoreception. Removal of the eyes however, abolished light-induced circadian phase-shifting. (Freedman et al., 1999). Overall the results suggest that the mouse eye contains specific photoreceptors for circadian regulation different from the visual photoreceptors. A study on normal rats, however, shows that the rod and cone photoreceptors for vision provide input to SCN neurons. (Aggelopoulos and Meissl, 2000). Thus, it is premature to rule out the visual photoreceptors from playing a role in circadian regulation in animals with normal, intact eyes.

If the rods and cones that mediate vision in rodents are not the primary photoreceptors for circadian regulation in rodents, what are the alternative candidates? Recent studies with various vertebrate species have identified several new molecules which may serve as circadian photopigments. These putative photopigments include both opsin-based molecules such as vertebrate ancient (VA) opsin (Soni and Foster, 1997), melanopsin (Provencio et al., 1998), and peropsin (Sun et al., 1997) as well as non-opsin molecules like biliverdin (Oren, 1996) and cryptochrome (Miyamoto and Sancar, 1998). Among these new photopigments, only melanopsin has been specifically localized to the human neural retina (Provencio et al., 2000) and cryptochrome has been localized to the mouse neural retina (Miyamoto and Sancar, 1998). The molecular identification of these candidate photoreceptors and their localization in the retina and/or neural components of the circadian system, make them well-suited to act as circadian phototransducers.

In summary, the present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm. Also, the present invention involves a light meter system for quantifying light which stimulates mammalian circadian, photoneural, and neuroendocrine systems, wherein the light meter has at least one light metering device to match peak wavelength sensitivity of mammalian photoreceptors for mammalian circadian, photoneural, and

BRA01-NP001

PATENT

neuroendocrine systems. Furthermore, the present invention exploits this peak wavelength sensitivity for novel light systems, novel translucent and transparent materials, and novel lamps or other light sources with or without filters. The present invention also involves the peak sensitivity as the focal point for treatment of mammals with a wide variety of disorders or deficits, including but not limited to, light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficit, hormone-sensitive cancers, and cardiovascular disorders.

DEFINITIONS

"Light responsive disorders" means any disorder responding to or preventable by phototherapy and includes, but is not limited to, seasonal affective disorders, sleep disorders, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers (including, but not limited to, breast cancers), and cardiovascular disorders.

"Light system" means a lamp, a lamp with filters, or another system or source for delivering light.

"Translucent or transparent material component" or "translucent or transparent material" includes, but is not limited to, at least one of the following: glasses, visors, windows, contacts, and filters. These materials may shape natural or artificial light.

"Light source" includes, but is not limited to, at least one of the following light sources: artificial light, natural light, and lamps.

SUMMARY OF THE INVENTION

The present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm. Also, the present invention involves a light meter system for quantifying light which stimulates mammalian circadian, photoneural, and neuroendocrine systems, wherein the light meter has at

BRA01-NP001

PATENT

least one light metering device to match peak wavelength sensitivity of mammalian photoreceptors for mammalian circadian, photoneural, and neuroendocrine systems, said peak wavelength ranging between 425-505 nm. Furthermore, the present invention exploits this peak wavelength sensitivity for novel light systems, novel translucent and transparent materials, and novel lamps or other light sources with or without filters. The present invention also involves exploiting this peak sensitivity for treatment of mammals with a wide variety of light responsive disorders or deficits, including but not limited to, light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficit, hormone-sensitive cancers, and cardiovascular disorders.

The light metering device is specifically configured to accurately quantify electromagnetic radiation that stimulates or regulates the circadian, photoneural, and neuroendocrine systems of healthy mammals or mammals having a variety of disorders. The meter's wavelength sensitivity matches the wavelength sensitivity of the photoreceptors for circadian, photoneural, and neuroendocrine regulation in mammals. This device is also used to quantify electromagnetic radiation which is optimum for treating Seasonal Affective Disorders (SAD) or other light-responsive disorders.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1: In this graph the bars represent group mean + SEM plasma melatonin values (N=8) before and after monochromatic light exposure at 505 nm. There were no significant variations across mean melatonin pre-light exposure values ($F=0.85$). Paired, two-tailed Students' t tests demonstrated which light intensities elicited a significant melatonin suppression.

Fig. 2: This graph illustrates group mean + SEM % control-adjusted melatonin change values (N=8) at 505 nm monochromatic light exposure. The figure shows that progressively higher light irradiance exposure produces increasingly greater melatonin suppression.

Fig. 3: This figure demonstrates the fitted fluence-response curve for photon density and % control-adjusted melatonin suppression (N=8). Each data point represents one group mean $\pm$ SEM.

BRA01-NP001

PATENT

Fig. 4: The bars represent group mean + SEM values relative to an equal photon dose of 4.2×10^{13} photons/cm². These data show that the 505 nm % control-adjusted plasma melatonin suppression is significantly stronger than that for 555 nm.

Fig. 5: This diagram illustrates the experimental electronic, optic and ganzfeld dome exposure array. This apparatus provides a uniform, patternless stimulus that encompasses the subject's entire visual field. For clarity, the subject's head is shown slightly withdrawn from the opening of the ganzfeld dome. During all light exposures, the subjects' bony orbits are completely enclosed in the dome walls providing complete exposure of their visual fields.

Fig. 6: In this graph the bars represent group mean + SEM plasma melatonin values before and after monochromatic light exposure at 460 nm in eight healthy subjects. There were no significant differences ($F=0.70$, $p=0.69$) across pre-exposure mean melatonin values. Light irradiances at or above $3.1 \mu\text{W}/\text{cm}^2$ elicited significant melatonin suppression.

Fig. 7: This figure illustrates the mean + SEM plasma melatonin percent control-adjusted change scores from eight healthy subjects exposed to different irradiances of monochromatic light at 460 nm. Progressively higher irradiance exposures at 460 nm produce progressively greater plasma melatonin percent control-adjusted change scores ($p<0.0001$).

Fig. 8: This graph demonstrates the best fit fluence-response curve for 460 nm exposures and percent control-adjusted melatonin suppression ($R^2 = 0.97$). Each data point represents one group mean $\pm$ SEM from eight healthy subjects.

Fig. 9: This figure illustrates the fitted univariant fluence-response curves for monochromatic light exposures and percent control-adjusted melatonin suppression for eight wavelengths of visible light. Each fluence-response curve is derived from eight healthy volunteers who participated in a complete, within-subjects experimental design. In each graph, the data points represent group means $\pm$ SEM. Each curve has a high coefficient of correlation (0.95 to 0.81).

Fig. 10: In this graph the bars represent group mean + SEM plasma melatonin values before and after exposure to $31.8 \mu\text{W}/\text{cm}^2$ monochromatic light at 420 nm in eight healthy subjects. This light irradiance induced a significant melatonin suppression ($p<0.003$).

Fig. 11: This graph demonstrates the action spectrum for percent control-adjusted melatonin suppression in 72 healthy human subjects. The filled circles represent the half-saturation constants of eight wavelengths from 440 to 600 nm which were normalized to the maximum response and plotted as log relative sensitivity. The open circle represents the estimated half-saturation constant derived from the 420 nm data. The line in the graph portrays the best fit template for vitamin A₁ retinaldehyde photopigments which predicts a maximal spectral absorbance (I_{max}) of 464 nm (Partridge and De Grip, 1991). There is a high coefficient of correlation for fitting this opsin template to the melatonin suppression data ($R^2 = 0.91$). The basis for the balanced wavelength peak sensitivity range is a calculation of approximately two standard deviations from 464 nm.

Fig. 12: This figure illustrates a comparison of the melatonin suppression and visual action spectra. The maximal spectral response and long wavelength limb of the melatonin suppression template is plotted along with the maximal spectral response and long wavelength limbs of the human rods and cones that support vision (Stockman and Sharpe, 1999). The shaded area around the 464 nm template represents $\pm$ SD from the data presented above.

DETAILED DESCRIPTION

The science of photobiology involves the study of how the infrared, visible and ultraviolet portions of the electromagnetic spectrum influence biological processes. There are two broad categories of light measurement techniques: radiometric and photometric. Each measurement technique has its merits and drawbacks relative to circadian regulation, neuroendocrine regulation and light therapy. Radiometry is based exclusively on the physical properties of light - its energy and wavelength. A radiometer measures the radiant power of a light source over a defined range of wavelengths. Radiometers can be configured to measure different bandwidths across the electromagnetic spectrum. The wavelengths within

BRA01-NP001

PATENT

the designated bandwidth can be detected equally, or they can be filtered for differential sensitivity across the various wavelengths.

In contrast to radiometry, photometry is based on the selective responsiveness of the human visual system. A photometer is simply a radiometer that has filters added to the detector which "shape" the detector sensitivity to resemble the luminance (brightness) response of the human visual system. Thus, photometry is a special branch of radiometry. Between individual humans, there are substantial differences in visual responses. The average photopic and scotopic visual functions are defined with reference to the adaptive state of the rod and cone photoreceptors in the human retina. Radiometers can be filtered to detect only those relative proportions of wavelengths that comprise the photopic or scotopic visual response. Photometers will detect photopic lux or scotopic lux, respectively. Specifically defined, lux measures are measures of illuminance - the amount of light, or luminous flux, falling on a surface. One photopic lux is one lumen per square meter (lm/m^2). The new metering system is configured to measure a new lighting unit which could be called "circadian lux" as opposed to photopic lux or scotopic lux.

Most investigators have operated from the assumption that light therapy is mediated via a photoreceptive mechanism in the human eye as opposed to a photoreceptive mechanism in the skin or some other part of the body. The data of the present invention demonstrate that the photoreceptive mechanism for the circadian and neuroendocrine system or the photoreceptive mechanism that mediates light therapy is not identical to the photoreceptive system that mediates the sensory capacity of vision.

Subjects, Materials and Methods

Subjects

The healthy females (N=6) and males (N=10) in this study had a mean $\pm$ SEM age of 25.7 ± 0.8 yrs, demonstrated normal color vision as measured by the Ishihara and Farnsworth Munsell D-100 tests (mean FM score: 64.2 ± 11.5), had a stable

BRA01-NP001

PATENT

sleeping pattern (mean wake-up time 7:30 AM $\pm$ 12 min), and signed an approved IRB consent document before participating.

Light exposure protocol

5

Each experiment began at midnight when subjects entered a dimly lit room (10 lux). One drop of 0.5% Cyclopentolate HCl was placed in each eye to dilate the pupils, and blindfolds were placed over subjects' eyes. Subjects remained sitting upright in darkness for 120 min. While still blindfolded and just prior to 2:00 AM, a blood sample was taken by venipuncture. During light exposure, each subject's head rested in an ophthalmologic head holder facing a Ganzfeld apparatus that provided a concave, patternless, white reflecting surface encompassing the subject's entire visual field. The subjects were exposed to the light stimulus from 2:00 to 3:30 AM. During this 90 min exposure, subjects sat quietly, kept their eyes open and gazed at a fixed target dot in the center of the Ganzfeld dome. Subject compliance for keeping their eyes open and the subjects' pupil size were monitored by a miniature video camera. At 3:30 AM, a second blood sample was taken. Each subject was exposed to complete darkness from 2:00 to 3:30 AM on their control night and was tested with at least 6 days between each nighttime exposure. Plasma samples were assayed for melatonin by RIA. (Rollag, 1976). The minimum detection limit of the assay was 0.5 - 2.0 pg/mL. Control samples had 8% and 14% intra-assay coefficients of variation.

10

15

20

Light production and measurement

25

Experimental light stimuli were produced by xenon arc lamps (Photon Technology Int'l , Inc., Princeton, NJ) enclosed in a light-proof chamber and cooled by high-speed fans and water circulation. An exit beam of light from each source was directed by a parabolic reflector, and excess heat in this beam was reduced by a water filter. Monochromatic wavelengths (10-11 nm half-peak bandwidth) were produced by a grating monochromator and light irradiance was controlled by a manual diaphragm. The resulting light beam was directed into the top area of a Ganzfeld dome and reflected evenly off the walls into volunteers' eyes. The entire reflecting

30

BRA01-NP001

PATENT

surface of the dome was coated with a white surface with a 95-99% reflectance efficiency over the 400 to 760 nm range. Routine measurement of the light irradiance ($\mu\text{W}/\text{cm}^2$) was done with a J16 Meter with a J6512 irradiance probe (Tektronix, Beaverton, OR). Experimental light stimuli reflected from the Ganzfeld domes were measured at volunteers' eye level immediately before and after the 90 min exposure. Additional measures were taken each half hour of the exposure to insure stimulus stability and enable intensity readjustment. Subjects in the 505 nm series were exposed to intensities ranging from 0.011 to $97 \mu\text{W}/\text{cm}^2$ (a 3 log unit photon density range of 10^{10} to 10^{13} photons/ cm^2). Subjects exposed to 555 nm received control or a $15 \mu\text{W}/\text{cm}^2$ (4.2×10^{13} photons/ cm^2) exposure.

Statistics

Two-tailed, Students' t tests were used to assess significance of raw melatonin change from 2:00 to 3:30 AM. These data were then converted to % control-adjusted melatonin change scores as described elsewhere. (Gaddy, 1993). For the 505 nm data, sets of pre-exposure melatonin values and % control-adjusted melatonin change scores were analyzed with one-way, repeated measures ANOVA. Significant differences between groups were assessed with post-hoc Scheffe F-tests; alpha was set at 0.05. For the 505 nm mean % control-adjusted melatonin suppression data, the computer program Origin 6.0 (Microcal, Northampton, MA) was used to fit a fluence-response curve to a 4 parameter model as described elsewhere (Brainard, 19893), and to test for goodness-of-fit of the data by coefficient of correlation.

Results

The full 505 nm data complement, from raw melatonin values to a final fluence-response curve, is illustrated in Figs. 1-3. Across all nights of testing, there were no significant differences ($F=0.85$) between sets of pre-exposure melatonin values indicating that plasma levels were consistent across the different study nights. Fig. 1 shows the mean $\pm$ SEM pre- and post-exposure melatonin values. One-way,

BRA01-NP001

PATENT

repeated measures ANOVA showed a significant effect of light intensity on plasma melatonin % change scores ($F=17.17$, $P<0.0001$). Paired t tests demonstrated that compared to the $0 \mu\text{W}/\text{cm}^2$ control night, all intensities at or above $5.5 \mu\text{W}/\text{cm}^2$ significantly suppressed melatonin ($P<0.05$ or less). In contrast, irradiances of 2.8, 1.4 and $0.011 \mu\text{W}/\text{cm}^2$ did not suppress melatonin compared to the control night (Scheffe F values: 0.97, 0.01 and 0.02, respectively). As illustrated in Fig. 2, all melatonin data were converted to control-adjusted % change scores. As with the melatonin % change scores, ANOVA showed a significant effect of light intensity on plasma melatonin % control-adjusted change scores ($F=13.59$, $P<0.0001$). Fig. 3 illustrates a best fit, sigmoidal fluence-response curve which plots melatonin % control-adjusted scores against stimulus photon density. The specific formula for this curve is included in the figure.

Subjects exposed to 555 nm received both control ($0 \mu\text{W}/\text{cm}^2$) and $15 \mu\text{W}/\text{cm}^2$ (4.2×10^{13} photons/ cm^2) exposures. For the control and light exposure nights, the mean pre-exposure raw melatonin scores were 64.4 ± 12.5 and 59.6 ± 6.2 , while the mean post-exposure scores were 62.6 ± 10.5 and 49.1 ± 6.0 , respectively. The modest drop in melatonin over the 90 min 555 nm light exposure period was not statistically significant ($t=1.69$, $df=7$, $P=0.14$). For comparison of responses to 505 nm and 555 nm, Fig. 4 illustrates % control-adjusted melatonin suppression relative at equal photon densities across the two wavelengths. These data reveal that 505 nm is significantly stronger than 555 nm in suppressing melatonin ($t=-3.04$, $df=14$, $P<0.01$).

Discussion

The data presented here demonstrate that: 1) there is a clear fluence-response relationship between graded light intensities of 505 nm light and melatonin suppression, and 2) that 505 nm light is significantly stronger than 555 nm light for suppressing melatonin in healthy, human subjects. Previous studies with animals and humans have illustrated fluence-response relationships for melatonin suppression and circadian phase-shifting with exposure to monochromatic light (Podolin, 1987; Brainard, 1988; Nelson, 1991) as well as white light (Brainard, 1983; Boivin, 1996). A recent study on human subjects suggests that a four parameter curve is optimal for

BRA01-NP001**PATENT**

modeling light-induced melatonin suppression and circadian phase shifting. (Zeitzer, 1997). That contention matches earlier animal data (Brainard, 1983) as well as the 505 nm data reported here.

The demonstration that 505 nm light is more potent than 555 nm light for controlling melatonin has important basic science and clinical implications. In humans, it is well-established that higher levels of ocular illumination are required for stimulating the circadian system than for supporting vision. (Lewy, 1980, Nelson, 1991; Czeisler, 1986). Consequently, many investigators have considered the three cone photopic visual system to be responsible for stimulating circadian and neuroendocrine responses since this part of the visual system is responsive to "bright" daytime levels of illumination. Over the past 20 years most of the published literature on human circadian responses to light reports light levels in terms of illuminance (lux, lumens) which is a specific measure based on the traditional sensitivity curve of the photopic visual system. The peak wavelength sensitivity of that curve is 555 nm. (Rodieck, 1998). Indeed, some researchers have argued that their data support the notion that the visual cones are involved in circadian phase-shifting in humans. (Zeitzer, 1997). If melatonin regulation is mediated primarily by the three cone photopic visual system, then 555 nm light should be the most potent wavelength for regulating melatonin. The data here do not support this view. On the contrary, 505 nm is significantly stronger, photon for photon, than 555 nm in suppressing melatonin. The clinical implication of this result is that it is not optimum to use photometric values (lux) for quantifying light used therapeutically in patients with certain sleep disorders or circadian disruption due to shiftwork or intercontinental jet travel as is the current standard practice. (1995 Special Issue, J Biol).

Ultimately, these studies open the door for redefining how light should be measured relative to the circadian system. The best circadian measurement system would match the action spectrum for human circadian regulation. That action spectrum would not only elucidate the relative circadian potencies of different wavelengths, but it should help identify the photoreceptor that initiates signals from the retina to the SCN.

In summary, monochromatic 505 nm light suppressed melatonin in a fluence-response manner, and is approximately four times stronger than a 555 nm stimulus at

BRA01-NP001

PATENT

an equal photon dose for melatonin suppression. These data demonstrate that the three cone system that is believed to mediate human photopic vision is not the primary photoreceptor system to transduce light stimuli for melatonin regulation.

5

Action Spectra Study design

Action spectra are determined by comparing the number of photons required for the same biological effect at different wavelengths (Lipson, 1994; Coohill, 1999). The melatonin suppression action spectrum described here was formed from fluence-response curves at 8 wavelengths between 440 nm and 600 nm. A within-subjects design was used for each fluence-response curve. For each wavelength studied, a set of 8 volunteers was exposed to a minimum of 8 different light irradiances on separate nights with at least 6 days between exposures. At the completion of that work, it was determined that a probe of sensitivity to monochromatic light below 440 nm was needed. Consequently, a group of 8 subjects was exposed to a single night of no light exposure and a single night of exposure to one irradiance of 420 nm light.

10

15

20

Subjects

25

30

Volunteers who were involved in shift work, planned long distance jet travel before or during the study period, or had irregular sleeping schedules were excluded from this study. The subject drop-out rate was 7.9%. The ethnic distribution of the 72 subjects who completed this study included 55 Caucasians, 9 Asians, 4 African Americans, 3 Hispanics and 1 individual of unknown ethnicity. Subjects who had a relatively stable daily sleeping pattern, passed a physical exam for general and ocular health, and signed an approved IRB consent document were accepted into this study. A total of 37 females and 35 males between 18-30 years old (mean $\pm$ SEM age = 24.5 $\pm$ 0.3) completed the study. The self-reported mean $\pm$ SE weekday wake-up time among subjects was 7:06 AM $\pm$ 18 min. All subjects were normal on the Ishihara and Farnsworth Munsell D-100 tests for color vision (mean $\pm$ SEM FM score: 51.4 $\pm$ 4.3).

Light exposure protocol for action spectra

Each experiment began at midnight when subjects entered a dimly lit room (10 lux or less). One drop of 0.5% Cyclopentolate HCl was placed in each eye to dilate the subjects' pupils and blindfolds were placed over their eyes. Subjects remained sitting upright for 120 minutes and listened to music on headphones or engaged in quiet conversation. While still blindfolded and just prior to 2:00 AM, a 10 ml blood sample was taken by venipuncture of the antecubital vein. Subjects' blindfolds were then removed and the subjects were exposed to the monochromatic light stimulus from 2:00 to 3:30 AM. During light exposure, each subject's head rested in an ophthalmologic head holder facing a ganzfeld apparatus that provided a concave, patternless reflecting surface encompassing each subject's entire visual field (see Figure 1). During this 90 minute exposure, subjects sat quietly, kept their eyes open and gazed at a fixed target dot in the center of the ganzfeld dome. Subject compliance for keeping their eyes open and the subjects' pupil size were monitored by a miniature video camera inside the ganzfeld dome. If the subjects began to close their eyes during the exposure period, the experimenters reminded them to keep their eyes completely open. At 3:30 AM, a second 10 ml blood sample was taken by venipuncture and the subjects were then permitted to leave the laboratory. Eight wavelengths were studied for this action spectrum (440, 460, 480, 505, 530, 555, 575 and 600 nm). Across these wavelengths, each subject was exposed to complete darkness from 2:00 to 3:30 AM on their control night and to a set of irradiances covering a 4 log unit photon density range of 10^{10} to 10^{14} photons/cm² on exposure nights. For the probe of sensitivity to monochromatic light at 420 nm, a group of 8 subjects were exposed to a single night of no light exposure and a single night of exposure to 420 nm light at $31.8 \mu\text{W}/\text{cm}^2$ (5.58×10^{13} photons/cm²).

Light production and measurement

As shown in Fig. 5, experimental light stimuli were produced by a 450 or 1200 W xenon arc lamp (Photon Technology Inc., Princeton, NJ). Each lamp was

BRA01-NP001

PATENT

enclosed in a light proof chamber and cooled by water circulation. An exit beam of light from each source was directed by a parabolic reflector and, for the 1200 W lamps, excess heat in the light beam was reduced by a water filter. Monochromatic wavelengths (10-14.5 nm half-peak bandwidths) were produced by a grating monochromator and light irradiance was controlled by a manual diaphragm. The resulting light beam was directed into the top area of a ganzfeld apparatus and reflected evenly off the walls of the ganzfeld dome into volunteers' eyes. The entire reflecting surface of the dome was coated with a white material (Spectralite) with a 95-99% reflectance efficiency over the 400 to 760 nm range. Routine measurement of the light irradiance ($\mu\text{W}/\text{cm}^2$) was done with a Tektronix J16 Radiometer/Photometer with a J6512 irradiance probe (Tektronix, Beaverton, OR). Experimental light stimuli reflected from the ganzfeld dome was measured at volunteers' eye level immediately before and after the 90 minute exposure. Additional measures were taken each half hour of the exposure to insure stimulus stability and enable readjustment of the intensity if it varied. These spot measures were taken with a ft-1" meter (Minolta, Osaka, Japan). Spectroradiometric assessment of the monochromatic wavelengths at the level of subjects' corneas was done with a portable spectroradiometer with a fiber optic sensor (Ocean Optics S2000). This equipment was calibrated with a standard lamp traceable to the National Institute of Standards and Technology (NIST).

In action spectroscopy, it is critical that the measured light stimuli are representative of the stimuli which actually reach the photoreceptors that mediate the photobiological response. In studies on light regulation of the circadian system, factors which can modify the measured stimulus before it reaches the photoreceptors include head and eye motion, squinting and eye closure, pupillary reflexes, and light transduction through the ocular media (Gaddy et al., 1993; Brainard et al., 1997). Most of these factors are controlled in the experimental technique described above. Concerning light transmission through ocular media, the cornea and aqueous and vitreous humors normally transmit nearly 100% of visible wavelengths to the retina and do not change substantively as the eyes age (Boettner and Wolter, 1962). In contrast, the aging human lens develops pigmentation that attenuates the transmission of shorter visible wavelengths to the retina (Lerman, 1987; Brainard et al., 1997). In

BRA01-NP001

PATENT

the present study, restricting the age of volunteers to 18-30 years controlled this factor. Measurements of mean transmittance of 36 postmortem human lenses in this age range showed relatively even transmission from 440 to 600 nm. In contrast, there was a mean 45% reduction in lens transmission at 420 nm compared to 460 nm (Brainard et al., 1997). Consequently, measured corneal light irradiances at 420 nm had to be adjusted to compensate for reduced stimulus transmission to the retina even in this relatively young study group.

Blood samples and melatonin assay

Blood samples were collected in glass vacutainers which contained EDTA. Plasma was separated by refrigerated centrifugation, aliquoted into cryogenic vials and stored at -20° C until assay. Melatonin concentrations were assayed by radioimmunoassay using antiserum described by Rollag and Niswender, (1976). Radiolabeled ligand was prepared by adding 10 µl of a dioxane solution containing 1 µmole 5-methoxytryptamine and 1 µmole tri-N-butylamine to 250 µCi (0.1 nmole) dried Bolton-Hunter Reagent (New England Nuclear Corp., Boston, MA). The reaction was allowed to proceed for one hour before adding 50 µl of aqueous sucrose (16 gm/ml electrophoresis buffer) and purifying product by disc gel electrophoresis. Duplicate aliquots of 200 µl of each unknown and control sample were extracted into 2 ml of chloroform. The chloroform was removed in a SpeedVac centrifuge (Savant Instruments, Holbrook, NY) and resuspended in 200 µl of assay buffer (phosphate buffered saline, pH 7.4, containing 0.1% gelatin with 100 mg thimerosal/liter as a preservative). The extracts were washed twice with 3 ml of petroleum ether, then evaporated to dryness in a SpeedVac before being resuspended in 200 µl of deionized water. Approximately 50,000 cpm of radiolabeled ligand and a 1:256,000 dilution of antiserum (R1055, 9/16/74) was added to each unknown and a triplicate 2-fold geometric series of standards ranging in concentration from 0.201 to 200 pg per 200 µl assay buffer. The final assay volume of buffer in each tube was 400 µl. At the end of the 48 hour incubation period, three ml of 95% ethanol (4° C) was added to each assay tube and the bound radioactivity precipitated by centrifugation at 2000 x g for 30 minutes. The supernatant was decanted and radioactivity in the precipitate was

BRA01-NP001

PATENT

quantified. The quantity of melatonin immunoreactivity in the samples was calculated with the use of a computer program (M.L. Jaffe and Associates, Silver Spring, MD; see Davis et al., 1980). All solutions were maintained at 4° C throughout the radioimmunoassay procedure. Assay results were not corrected for recovery (which has proven to be >95% in independent trials). The minimum detection limit of the assay is 0.5-2.0 pg/ml.

Statistics for action spectra

Two-tailed, paired Student's t tests were used to assess statistical significance of raw melatonin change from 2:00 to 3:30 AM. Percent melatonin change scores were determined by the following formula:

$$\text{Percent Melatonin Change Score} = 100 \times \frac{03:30 \text{ h melatonin} - 02:00 \text{ h melatonin}}{02:00 \text{ h melatonin}}$$

Percent melatonin change scores then were normalized to percent control-adjusted change scores by subtracting the control (no light) condition percent change scores for each subject from that same subject's light exposure score. This technique accounts for the normal individual rise or fall in plasma melatonin levels with respect to the light-induced changes (Gaddy et al., 1993; Brainard et al., 1997). For data from each wavelength, complete sets of pre-exposure melatonin values, percent melatonin change scores, and percent control-adjusted melatonin change scores were analyzed with one way, repeated-measures ANOVA. Significant differences between groups were assessed with post-hoc Scheffe F-tests with alpha set at 0.05. The group of single fluence-response curves (one for each wavelength) was fitted to a parametric model in which the melatonin response (Y) to a photon dose (X) is predicted by: the theoretical initial Y-response (0 dose) for the curve (A₁); the theoretical final Y-response ("infinite" dose) for the curve (A₂); the dose producing a response halfway

between A₁ and A₂ (X₅₀ or ED₅₀); and the slope estimator (p) for the slope of the curve between A₁ and A₂. The equation is:

$$Y = \frac{A_1 - A_2}{1 + (X/X_{50})^p} + A_2$$

The computer program Origin 6.0 (Microcal, Northampton, MA) was used to fit the fluence-response curves to the data. From extensive experience in our laboratory, a saturating 90 minute light exposure produces a maximum mean percent control-adjusted plasma melatonin suppression ranging from 60 to 80% depending on the particular group of subjects being tested (Gaddy et al., 1993; Ruberg et al., 1996; Wang et al., 1999; Brainard et al., 2000; 2001). To form an analytical action spectrum, it is necessary to determine if all fluence-response curves can be fit to a univariant sigmoidal curve (Lipson, 1994; Coohill, 1991; 1999). To do this, sigmoid curves were fitted to the five fluence-response curves between 440 nm and 530 nm which reached a mean percent control-adjusted melatonin suppression of 60-80% by constraining the A₁ factor (theoretical initial Y-response) to 0 since no light exposure should yield a 0% control-adjusted plasma melatonin suppression. From this set of curves, a mean A₂ (theoretical final Y-response or "infinite" dose for the curve), and a mean p (slope estimator) was calculated. Subsequently, all 8 data sets (including the data sets which did not reach saturation) were then fitted to sigmoid curves that constrained A₂ and p to these means and constrained A₁ to 0. Each calculated curve was tested for goodness-of-fit of the data by coefficient of correlation.

Melatonin action spectrum

This action spectrum was formed from the photon density which elicited the half-saturation constant (ED₅₀) of the percent control-adjusted melatonin suppression for each of the 8 wavelengths. These half-saturation constants were derived from the 8 univariant fluence-response curves described above. The half-saturation constants

BRA01-NP001

PATENT

were then normalized to the maximum response and plotted as relative sensitivity. The relative quantum sensitivity from each group of subjects was then graphically plotted (quanta/wavelength) to illustrate the resultant action spectra for melatonin suppression in humans. A predicted peak sensitivity for this action spectrum was determined by fitting a vitamin A₁-retinaldehyde photopigment template to the data by a modification of the method described by MacNichol (1983). Specifically, the long wavelength limb of vitamin A₁-based photopigments can be considered linear within the 10-90% sensitivity range when plotted on a frequency abscissa. To select the best fit vitamin A₁ template, the normalized 10-90% long wavelength melatonin ED₅₀ data were fitted to a series of vitamin A₁-based templates within the 10-90% sensitivity range of the templates' long-wavelength limbs (Partridge and De Grip, 1991). Pearson correlation coefficients derived from fitting the melatonin data to the templates indicated the optimum fitting template.

Results of action spectra

Variations in pupillary dilation, exposure time and melatonin assay

Individuals vary slightly in their pupil size and response to mydriatic agents. Mean $\pm$ SD pupillary dilation was 7.19 ± 0.88 mm for all 72 subjects across all nights of exposures. There were no significant pupil size changes during the light exposures. Similarly, there is a small degree of variability in exact light exposure durations due to slight experimental delays. Across 627 single-subject experiments, the mean $\pm$ SD exposure duration was 90.6 ± 2.1 minutes. A total of 53 assays were run to quantify melatonin in plasma samples collected during this project. Coefficients of variation calculated from control samples assayed as 19.2 pg/ml and 90.0 pg/ml had 10.8% and 4.0% for intra-assay coefficients of variation, respectively. The inter-assay coefficients of variation were 13.5% and 10.2%.

Fluence-response data at 460 nm

Since the predicted peak of the final action spectrum is 464 nm, the full data complement, from raw melatonin values to a final fluence-response curve for the nearby monochromatic stimulus at 460 nm, is illustrated in Figs. 2-4. This fluence-response study at 460 nm was done with 8 subjects (4 males, 4 females). Across these subjects on all nights of testing, there were no significant differences ($F=0.70$, $p=0.69$) between sets of pre-exposure values indicating that baseline nocturnal melatonin levels were consistent across the different nights of study. Fig. 6 shows the mean + SEM pre- and post-exposure (2:00 to 3:30 AM) melatonin values (mean range 72.1-29.3 pg/ml). At 460 nm, exposure to irradiances of $2.3 \mu\text{W}/\text{cm}^2$ and lower did not significantly suppress plasma melatonin. In contrast, exposures of $3.1 \mu\text{W}/\text{cm}^2$ and higher elicited significant melatonin suppressions ($p < 0.03$ or less).

For comparative purposes, all melatonin data were converted to plasma melatonin percent control-adjusted change scores. As illustrated in Fig. 7, one-way, repeated measures ANOVA showed a significant effect of light intensity on plasma melatonin percent control-adjusted change scores ($F=14.92$, $p<0.0001$). Post-hoc tests on plasma melatonin percent control-adjusted scores demonstrated that all intensities at or above $3.1 \mu\text{W}/\text{cm}^2$ significantly suppressed melatonin more than $0.012 \mu\text{W}/\text{cm}^2$ ($p<0.05$ or less). Similarly, all irradiances at or above $12.1 \mu\text{W}/\text{cm}^2$ significantly suppressed melatonin more than $1.5 \mu\text{W}/\text{cm}^2$. Finally, both 24.2 and $42.2 \mu\text{W}/\text{cm}^2$ exposures elicited significantly higher plasma melatonin percent control-adjusted change scores compared to an irradiance of $2.3 \mu\text{W}/\text{cm}^2$.

The data from Fig. 7 can be mathematically converted into a best fit, sigmoidal curve which plots melatonin suppression against stimulus photon density. The specific formula for this curve is shown below and has a 0.97 coefficient of correlation (R^2).

$$y = \frac{7.17 - 73.4}{1 + (x/8.29)^{1.23}} + 73.4$$

As shown in **Fig. 8**, this curve illustrates the fluence-response interaction between mean $\pm$ SEM melatonin percent control-adjusted change scores and the photon density of the monochromatic light.

5

Fluence-response data for all 8 wavelengths

10

As shown in **Figs. 6-8**, there is a clear, fluence-response relationship between graded photon densities of monochromatic 460 nm light and melatonin suppression. Data from each of the 8 wavelengths tested in this study fit four-parameter sigmoidal curves with high coefficients of correlation. Specifically, wavelengths at 440, 460, 480, 505, 530, 555, 575 and 600 nm had respective coefficients of correlation (R^2): 0.99, 0.97, 0.95, 0.97, 0.98, 0.92, 0.96, and 0.97. As described in the Methods, to form an analytical action spectrum, all fluence-response curves must be fit to a univariant sigmoidal curve (Lipson, 1994; Coohill, 1999). The univariant curve model for the data in this study has the factors of $A_1=0$, $A_2=66.9$, and $p=1.27$. Figure 5 illustrates all 8 univariant fluence-response curves from this study. As with previous circadian analytical action spectra (Takahashi et al., 1984; Provencio and Foster, 1995; Yoshimura and Ebihara, 1996), full range fluence-response curves were not elicited above 550 nm. Despite this, standard photobiological curve fitting methods could be used to fit the data from all eight wavelengths in the present study to univariant, sigmoidal functions. When fit to a univariant fluence-response curve with these factors, the data from exposures to 440, 460, 480, 505, 530, 555, 575 and 600 nm have high coefficients of correlation of 0.91, 0.95, 0.93, 0.94, 0.92, 0.90, 0.95, and 0.81, respectively.

15

20

25

Melatonin suppression response to 420 nm at a single intensity

30

Given the high sensitivity of subjects to short wavelength light as shown in **Fig. 9**, it was determined that a probe of sensitivity to monochromatic light below 440 nm was needed. On the control night when the eight volunteers were exposed to

darkness only, their raw mean melatonin levels at 2:00 and 3:30 AM were 69.4 and 76.0 pg/ml, respectively. That small increase was not statistically significant ($t=-1.15$, $p=0.29$). As shown in Fig. 10, when these volunteers were exposed to 420 nm light at 31.8 $\mu\text{W}/\text{cm}^2$ (5.58×10^{13} photons/ cm^2), raw mean melatonin levels at 2:00 and 3:30 AM were 76.4 and 47.6 pg/ml, respectively. That decrease in melatonin was statistically significant ($t=4.67$, $p<0.003$). For comparative purposes, this single melatonin suppression response was fitted to the univariant fluence-response curve formula used for all of the data in Fig. 9. The resulting curve estimated a half-maximum (X_{50} or ED_{50}) melatonin suppression response for 420 nm of 1.83×10^{13} photons/ cm^2 .

Action spectrum for melatonin suppression

Action spectra are determined by comparing the number of photons required for the same biological effect at different wavelengths (Smith, 1989; Coohill, 1999). For this experiment, the action spectrum was formed from the photon density which elicited the half-saturation constant (X_{50} or ED_{50}) of the percent control-adjusted melatonin suppression for each of the eight wavelengths. The half-saturation constants were derived from the eight univariant fluence-response curves shown in Fig. 9 and the one estimated half-saturation constant from the data shown in Fig. 10. The relative quantum sensitivity from each group of subjects was plotted in Fig.11 (quanta/wavelength) to illustrate the resultant action spectra for human melatonin suppression. When the data were aligned to the best-fit template for vitamin A₁-retinaldehyde photopigments, this action spectrum predicted a peak spectral sensitivity (I_{max}) of 464 nm. There was a strong coefficient of correlation between the data and this fitted opsin nomogram ($R^2=0.91$).

Comparison of action spectra

The action spectrum for the photoreceptor system which provides input to the pineal gland appears to be distinct from the action spectra for the classical human

visual photoreceptor systems. To illustrate this, the maximal spectral absorbencies and long wavelength limbs of the human rod and cone photoreceptors that support vision (Stockman and Sharpe, 1999) are illustrated in Figure 8 along with the maximal spectral absorbence and long wavelength limb of the melatonin action spectrum. The shaded area around the melatonin action spectrum illustrates $\pm$ SD for this function.

Discussion of action spectra

The action spectrum presented here is based on univariant fluence-response curves for melatonin suppression by eight monochromatic light wavelengths in healthy subjects. These data fit a vitamin A₁ opsin template with 446-477 nm providing the strongest circadian input for melatonin regulation. These results suggest a novel photopigment in the human eye may be primarily responsible for melatonin regulation and may be distinct from the individual rod and cone photoreceptors for vision.

In developing a fluence-response curve, a complete within-subjects experimental design produces the most reliable results. When subjects are studied over a two to four month period, however, lack of stability in the subjects' circadian entrainment can introduce variability in light-induced melatonin suppression. This study accepted only volunteers who reported regular bed and wake times and their melatonin rhythms appeared to have been stable during the course of the study. As shown in the 2:00 AM melatonin values (Fig. 6), there were no significant differences between sets of pre-exposure values indicating that baseline melatonin levels were consistent across the different study nights. This phenomenon has been documented for the 505 nm fluence-response group as well as in other similarly controlled studies (Brainard et al., 1997; 2000; 2001; Wang et al., 1998). This within-subject stability of the melatonin rhythm over time has been frequently confirmed in the literature (Waldhauser and Dietzel, 1985; Arendt, 1988; 1998).

The data from each wavelength studied fit a univariant four parameter sigmoidal curve with a high coefficient of correlation. The univariance of these curves is consistent with, but does not prove, the hypothesis that melatonin

BRA01-NP001

PATENT

suppression is modulated by a single photoreceptor type. Previous studies with animals and humans have illustrated similar fluence-response relationships for melatonin suppression and other circadian responses with monochromatic and broad spectrum light (Brainard et al., 1983; 1988; Podolin et al., 1987; McIntyre et al., 1989; Nelson and Takahashi, 1991; Zeitzer et al., 2000; Dkhissi-Benyahya et al., 2000). The initial attempts to define circadian and neuroendocrine responses to photons of different wavelength began with polychromatic action spectra which tested single irradiances of broader light bandwidths in various rodent species. These polychromatic action spectra were reasonably consistent in indicating that the spectral region between 450-550 nm provides the strongest stimulation of circadian and neuroendocrine responses in rodents (for review: Brainard et al., 1999). Analytic action spectra, based on sets of fluence-response curves at different monochromatic wavelengths, are superior for identifying photoreceptors that mediate photobiological responses (Lipson, 1994; Coohill, 1999).

There are four analytic action spectra on circadian and neuroendocrine regulation in hamsters, rats and mice (Takahashi et al., 1984; Bronstein et al., 1987; Provencio and Foster, 1995; Yoshimura and Ebihara, 1996). Data from these action spectra have been fitted to spectral sensitivity curves for retinal-based visual photopigments. This curve fitting is predicated on the assumption that a retinal-based molecule transduces light stimuli for circadian regulation, and allows the prediction of the shape of the photopigment absorption spectrum as well as its peak sensitivity (I_{max}). Across these studies which employed different circadian endpoints, the predicted I_{max} ranges from 480-511 nm and is surrounded by a broad region of high sensitivity. From these results, different photopigments have been suggested to be responsible for circadian regulation, including rhodopsin, a rhodopsin-like molecule, a middle wavelength cone photopigment, or an ultraviolet cone photopigment.

It is commonly believed that the photopic visual system has a peak wavelength sensitivity around 555 nm (Rodieck, 1998). Many investigators have hypothesized that the photopic visual system mediates circadian and neuroendocrine responses, since this part of the visual system is responsive to "bright" daytime levels of illumination. Previous data (Brainard et al., 2001) and those presented above do not support this view. The results clearly demonstrate that 555 nm is significantly weaker in suppressing melatonin compared to an equal photon density of 460 nm. Thus, the

BRA01-NP001

PATENT

photopic system is not likely to be the primary input for circadian regulation. Demonstrating that the photopic visual system is not the principal phototransducer for melatonin regulation does not preclude it from having any role in circadian input. Indeed, recent studies suggest that visual cones may be involved in circadian regulation. Recordings from SCN neurons in rats indicate that the visual rods and cones provide input to cells of the rat SCN (Aggelopoulos and Meissl, 2000). Similarly, a human phase-shifting study suggests that, under some circumstances, the visual long wavelength-sensitive cone may also mediate circadian vision in humans (Zeitler et al., 1997).

The data presented here do not support the view that any of the known visual photoreceptors provide the primary input for melatonin regulation. Fig. 10 shows that none of the action spectra for individual visual photoreceptor systems match the action spectrum for melatonin suppression. If the photoreceptors that mediate vision in humans are not the primary photoreceptors for circadian regulation, what are the alternative candidates? Recent studies with various vertebrate species have identified several new molecules which may serve as circadian photopigments. These putative photopigments include both opsin-based molecules such as vertebrate ancient (VA) opsin (Soni and Foster, 1997), melanopsin (Provencio et al., 1998), and peropsin (Sun et al., 1997), as well as non-opsin molecules like biliverdin (Oren, 1996) and cryptochrome (Miyamoto and Sancar, 1998). Among these new photopigments, only melanopsin has been specifically localized to the human neural retina (Provencio et al., 2000) and cryptochrome has been localized to the mouse neural retina (Miyamoto and Sancar, 1998). Cryptochromes have been studied extensively as circadian photoreceptors in plants and insects (Ahmad and Cashmore, 1993; Stanewsky et al., 1998), and have been proposed as circadian photoreceptors in mammals (Miyamoto and Sancar, 1998; Thresher et al., 1998). The contention that cryptochromes serve as circadian photoreceptors in humans or other mammals, however, remains controversial (van der Horst et al., 1999; Griffin et al., 1999; von Schantz et al., 2000).

The action spectrum presented here matches a vitamin A₁-retinaldehyde photopigment template which supports the hypothesis that one of the new opsin photopigment candidates provides primary photic input for melatonin regulation in humans. The molecular identification of candidate opsin or non-opsin photoreceptors

and their localization in the retina and/or neural components of the circadian system make them well-suited to act as circadian phototransducers.

Are the effects of light on melatonin suppression relevant to general circadian regulation? Studies have shown that hamsters have a higher intensity threshold for light-induced phase-shifts of wheel running rhythms than for melatonin suppression (Nelson and Takahashi, 1991). Recently, however, a study on humans showed that the 50% response sensitivity for circadian phase-shifting (119 lux) was only slightly higher than that for melatonin suppression (106 lux) with white light (Zeitzer et al., 2000). It is possible that there are separate photoreceptors for mediating circadian entrainment versus acute suppression of melatonin. It is reasonable, however, to conclude that a variety of non-visual effects of light such as melatonin suppression, entrainment of circadian rhythms, and possibly some clinical responses to light are mediated by a shared photoreceptor system.

In general, relatively high light illuminances ranging from 2,500 to 12,000 lux are used for treating winter depression, selected sleep disorders and circadian disruption (Wetterberg, 1993; Lam, 1998). Although these light levels are therapeutically effective, some patients complain that they produce side effects of visual glare, visual fatigue, photophobia, ocular discomfort, and headache. Determining the action spectrum for circadian regulation can lead to improvements in light therapy. Total illuminances for treating a given disorder can be reduced as the wavelength emissions of the therapeutic equipment are optimized.

Modern industrialized societies employ light extensively in homes, schools, work places and public facilities to support visual performance, visual comfort, and aesthetic appreciation within the environment. Since light is also a powerful regulator of the human circadian system, future lighting strategies will need to provide illumination for human visual responses as well as homeostatic responses. The action spectrum presented here suggests that there are separate photoreceptors for visual and circadian responses to light in humans. Hence, new approaches to architectural lighting may be needed to optimally stimulate both the visual and circadian systems.

In conclusion, this study characterizes the wavelength sensitivity of the ocular photoreceptor system for regulating the human pineal gland by establishing an action spectrum for light-induced melatonin suppression. The results identify 446-477 nm portion of the spectrum as the most potent wavelengths providing circadian input for

BRA01-NP001**PATENT**

regulating melatonin secretion. These data suggest that the primary photoreceptor system for melatonin suppression is distinct from the rod and cone photoreceptors for vision. Finally, this action spectrum suggests that there is a novel retinaldehyde photopigment which mediates human circadian photoreception. These findings open the door for optimizing the utilization of light in both therapeutic and architectural applications.

5

REFERENCES

Aggelopoulos NC, Meissl H (2000) Responses of neurones of the rat suprachiasmatic nucleus to retinal illumination under photopic and scotopic conditions. J Physiol 523:211-222.

Ahmad M, Cashmore AR (1993) HY4 gene of *A. thaliana* encodes a protein with characteristics of a blue-light photoreceptor. Nature 366:162-166.

Arendt J (1988) Melatonin [Review]. Clin Endocrinol 29:205-229.

Arendt J (1998) Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod 3:13-22.

Boettner EA, Wolter JR (1962) Transmission of the ocular media. Invest Ophthalmol Vis Sci 1:776-783.

Boivin DB, JF Duffy, RE Kronauer, CA Czeisler (1996) Dose-response relationships for resetting of human circadian clock by light. Nature 379: 540-542.

Brainard GC, Richardson BA, King TS, Matthews SA, Reiter RJ (1983) The suppression of pineal melatonin content and N-acetyltransferase activity by different light irradiances in the Syrian hamster: a dose-response relationship. Endocrinology 113:293-296.

Brainard GC, Lewy AJ, Menaker M, Miller LS, Fredrickson RH, Weleber RG, Cassone V, Hudson D (1988) Dose-response relationship between light irradiance and the suppression of melatonin in human volunteers. Brain Res 454:212-218.

Brainard GC, Rollag MD, Hanifin JP (1997) Photic regulation of melatonin in humans: ocular and neural signal transduction. J Biol Rhythms 12:537-546.

BRA01-NP001

PATENT

5 Brainard GC, Greeson JM, Hanifin JP (1999) Action spectra for circadian and neuroendocrine regulation in mammals. In: Measurements of Optical Radiation Hazards (Matthes R, Sliney D, Didomenico S, Murray P, Phillips R, Wengraitis S, eds), pp 131-142. Munchen, Germany: ICNIRP.

10 Brainard GC, Rollag MD, Hanifin JP, van den Beld G, Sanford B (2000) The effect of polarized versus non-polarized light on melatonin regulation in humans. Photochem Photobiol 71:766-770.

15 Brainard GC, Hanifin JP, Rollag MD, Greeson J, Byrne B, Glickman G, Gerner E, Sanford B (2001) Human melatonin regulation is not mediated by the three cone photopic visual system. J Clin Endocrinol Metab 86:433-436.

20 Bronstein DM, Jacobs GH, Haak KA, Neitz J, Lytle LD (1987) Action spectrum of the retinal mechanism mediating nocturnal light-induced suppression of rat pineal gland N-acetyltransferase. Brain Res 406:352-356.

Coohill TP (1991) Action spectra again? Photochem Photobiol 54:859-870.

25 Coohill TP (1999) Photobiological action spectra- what do they mean? In: Measurements of Optical Radiation Hazards (Matthes R, Sliney D, Didomenico S, Murray P, Phillips R, Wengraitis S, eds), pp 27-39. Munchen, Germany: ICNIRP.

30 Czeisler CA, Shanahan TL, Klerman EB, Martens H, Brotman DJ, Emens JS, Klein T, Rizzo JF, III (1995) Suppression of melatonin secretion in some blind patients by exposure to bright light. N Engl J Med 332:6-11.

Czeisler CA, Allan JS, Strogatz SH, Ronda JM, Sanchez R, Rios CD, Freitag WO, Richardson GS, Kronauer RE (1986) Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science 233: 667-671.

Davis SE, Munson PJ, Jaffe ML, Rodbard D (1980) Radioimmunoassay data processing with a small programmable calculator. Journal of Immunoassay 1:15-25.

BRA01-NP001

PATENT

Dkhisssi-Benyahya O, Sicard B, Cooper HM (2000) Effects of irradiance and stimulus duration on early gene expression (fos) in the suprachiasmatic nucleus: temporal summation and reciprocity. *J Neurosci* 20:7790-7797.

5

Foster RG, Provencio I, Hudson D, Fiske S, DeGrip W, Menaker M (1991) Circadian photoreception in the retinally degenerate mouse (*rd/rd*). *J Comp Physiol [A]* 169:39-50.

10

Freedman MS, Lucas RJ, Soni B, von Schantz M, Munoz M, David-Gray Z, Foster RG (1999) Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors. *Science* 284:502-504.

15

Gaddy JR, Rollag MD, Brainard GC (1993) Pupil size regulation of threshold of light-induced melatonin suppression. *J Clin Endocrinol Metab* 77:1398-1401.

20

Goto M, Ebihara S 1990 The influence of different light intensities on pineal melatonin content in the retinal degenerate C3H mouse and the normal CBA mouse. *Neurosci Lett*. 108:267-272.

Griffin EA, Staknis D, Weitz CJ (1999) Light-independent role of Cry1 and Cry2 in the mammalian circadian clock. *Science* 286:768-771.

25

Klein DC, Moore RY, Reppert SM (1991) *Suprachiasmatic Nucleus: The Mind's Clock*. Oxford: Oxford University Press.

Klein DC, Weller JL (1972) Rapid light-induced decrease in pineal serotonin N-acetyltransferase activity. *Science* 177:532-533.

30

Lam RW (1998) *Seasonal Affective Disorder and Beyond: Light Treatment for SAD and Non-SAD Disorders*. Washington, D.C.: American Psychiatric Press.

Lerman S (1987) Chemical and physical properties of the normal and aging lens: Spectroscopic (UV, fluorescence, phosphorescence, and NMR) analyses. *Am J Opt Physiol Optics* 64:11-22.

5

Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP (1980) Light suppresses melatonin secretion in humans. *Science* 210:1267-1269.

10

Lipson ED (1994) Action spectroscopy: methodology. In: *Organic Photochemistry and Photobiology* (Horspool WM and Song P-S, eds), pp 1257-1266. New York: CRC Press.

15

Lucas RJ, Foster RG (1999) Neither functional rod photoreceptors nor rod or cone outer segments are required for the photic inhibition of pineal melatonin. *Endocrinology* 140:1520-1524.

20

MacNichol EF, Levine JS, Mansfield RJW, Lipetz LE, Collins BA (1983) Microspectrophotometry of visual pigments in primate photoreceptors. In: *Colour Vision* (Mollon JD and Sharpe LT, eds), pp 14-38. Cambridge, England: Academic Press.

25

McIntyre IM, Norman TR, Burrows GD, Armstrong SM (1989) Human melatonin suppression by light is intensity dependent. *J Pineal Res* 6:149-156.

30

Miyamoto Y, Sancar A (1998) Vitamin B2-based blue-light photoreceptors in the retinohypothalamic tract as the photoactive pigments for setting the circadian clock in mammals. *Proc Natl Acad Sci U S A* 95:6097-6102.

Moore RY (1983) Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. *Federation Proceedings* 42:2783-2789.

Moore RY, Lenn NJ (1972) A retinohypothalamic projection in the rat. *J Comp Neurol*. 146:1-14.

BRA01-NP001

PATENT

Morin LP (1994) The circadian visual system. *Brain Res Brain Res Rev* 19:102-127.

5 Nelson DE, Takahashi JS (1991) Comparison of visual sensitivity for suppression of pineal melatonin and circadian phase-shifting in the golden hamster. *Brain Res* 554:272-277.

10 Oren DA (1996) Humoral phototransduction: blood is a messenger. *The Neuroscientist* 2:207-210.

15 Partridge JC, De Grip WJ (1991) A new template for rhodopsin (vitamin A1 based) visual pigments. *Vision Res* 31:619-630.

20 Pevet P, Heth G, Hiam A, Nevo E (1984) Photoperiod perception in the blind mole rat (*Spalax ehrenbergi*, Nehring): involvement of the Harderian gland, atrophied eyes, and melatonin. *J Exp Zool* 232:41-50.

25 Podolin PC, Rollag MD, Brainard GC (1987) The suppression of nocturnal pineal melatonin in the Syrian hamster: dose-response curves at 500 nm and 360 nm. *Endocrinology* 121:266-270.

30 Provencio I, Foster RG (1995) Circadian rhythms in mice can be regulated by photoreceptors with cone-like characteristics. *Brain Res* 694:183-190.

35 Provencio I, Jiang G, De Grip WJ, Hayes WP, Rollag MD (1998) Melanopsin: an opsin in melanophores, brain, and eye. *Proc Natl Acad Sci U S A* 95:340-345.

40 Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD (2000) A novel human opsin in the inner retina. *J Neurosci* 20:600-605.

45 Reiter RJ (1991) Pineal melatonin: cell biology of its synthesis and of its physiological interactions. *Endocr Rev* 12:151-180.

BRA01-NP001

PATENT

Rodieck RW (1998) *The First Steps in Seeing*, Sunderland, Massachusetts: Sinauer Associates, Inc.

5 Rollag MD, Niswender GD (1976) Radioimmunoassay of serum concentrations of melatonin in sheep exposed to different lighting regimens. *Endocrinology* 98:482-489.

10 Ruberg FL, Skene DJ, Hanifin JP, Rollag MD, English J, Arendt J, Brainard GC (1996) Melatonin regulation in humans with color vision deficiencies. *J Clin Endocrinol Metab* 81:2980-2985.

15 Schwartz WJ, Busis NA, Hedley-Whyte ET (1986) A discrete lesion of ventral hypothalamus and optic chiasm that disturbed the daily temperature rhythm. *J Neurol.* 233:1-4.

Smith KC (1989) *The Science of Photobiology*. New York: Plenum Press.

20 Soni BG, Foster RG (1997) A novel and ancient vertebrate opsin. *FEBS Lett* 406:279-283.

25 Stanewsky R, Kaneko M, Emery P, Beretta B, Wager-Smith K, Kay SA, Rosbash M, Hall JC (1998) The cry mutation identifies cryptochrome as a circadian photoreceptor in drosophila. *Cell* 95:681-692.

Stockman A, Sharpe LT (1999) Cone spectral sensitivities and color matching. In: *Color Vision: From Genes to Perception* (Gegenfurtner KR and Sharpe LT, eds), pp 53-87. Cambridge, United Kingdom: Cambridge University Press.

30 Sun H, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J (1997) Peropsin, a novel visual pigment-like protein located in the apical microvilli of the retinal pigment epithelium. *Proc Natl Acad Sci U S A* 94:9893-9898.

BRA01-NP001

PATENT

Takahashi JS, DeCoursey PJ, Bauman L, Menaker M (1984) Spectral sensitivity of a novel photoreceptive system mediating entrainment of mammalian circadian rhythms. *Nature* 308:186-188.

5

Thresher RJ, Vitaterna MH, Miyamoto Y, Kazantsev A, Hsu DS, Petit C, Selby CP, Dawut L, Smithies O, Takahashi JS, Sancar A (1998) Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses. *Science* 282:1490-1494.

10

van der Horst GTJ, Muijtjens M, Kobayashi K, Takano R, Kanno S, Takao M, de Wit J, Verkerk A, Eker APM, van Leenen D, Buijs R, Bootsma D, Hoeijmakers JHJ, Yasui A (1999) Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms. *Nature* 398:627-630.

15

von Schantz M, Provencio I, Foster RG (2000) Recent developments in circadian photoreception: more than meets the eye. *Invest Ophthalmol Vis Sci* 41:1605-1607.

20

Waldhauser F, Dietzel M (1985) Daily and annual rhythms in human melatonin secretion: role in puberty control. *Ann N Y Acad Sci* 453:205-214.

25

Wang JY, Hanifin JP, Rollag MD, Brainard GC (1999) Ocular regulation of the human pineal gland: the significance of total retinal exposure for melatonin suppression. In: *Biologic Effects of Light 1998* (Holick M and Jung EG, eds), pp 367-374. Boston, Massachusetts: Kluwer Academic Publishers.

30

Webb SM, Champney TH, Lewinski AK, Reiter RJ (1985) Photoreceptor damage and eye pigmentation: influence on the sensitivity of rat pineal N-acetyltransferase activity and melatonin levels to light at night. *Neuroendocrinology* 40:205-209.

35

Wehr TA (1991) The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). *J Clin Endocrinol Metab* 73:1276-1280.

Wetterberg L (1993) *Light and Biological Rhythms in Man*. Stockholm: Pergamon Press.

BRA01-NP001

PATENT

Yoshimura T, Ebihara S (1996) Spectral sensitivity of photoreceptors mediating phase-shifts of circadian rhythms in retinally degenerate CBA/J (*rd/rd*) and normal CBA/N (+/+) mice. *J Comp Physiol [A]* 178:797-802.

5

Zeitzer JM, Kronauer RE, Czeisler CA (1997) Photopic transduction implicated in human circadian entrainment. *Neurosci Lett* 232:135-138.

10

Zeitzer JM, Dijk D-J, Kronauer RE, Brown EN, Czeisler CA (2000) Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. *J Physiol* 526:695-702.

1995 Special Issue: Task force report on light treatment for sleep disorder *J Biol Rhythms* 10: 99-176.

15

BRA01-NP001

PATENT

WHAT IS CLAIMED IS:

- 5
1. A method of treating or preventing a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system emits a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.
- 10
2. The method of **Claim 1**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.
- 15
3. A method of treating a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system excludes emission of a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.
- 20
4. The method of **Claim 3**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.
- 25
5. A light system, comprising at least one light source, said light source emitting a balance of wavelengths to stimulate a mammalian circadian, photoneural, or neuroendocrine system, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.
- 30

BRA01-NP001

PATENT

6. A light system, comprising at least one light source, said light source
excluding emission of a balance of wavelengths to stimulate a mammalian circadian,
5 photoneural, or neuroendocrine system, said balance of wavelengths having a peak
sensitivity ranging from 425 –505 nm.

7. A transparent composition, comprising at least one light filtering component,
said light filtering component specifically transmitting a balance of wavelengths for
10 stimulating a mammalian circadian, photoneural, or neuroendocrine system, said
balance of wavelengths having a peak transmittance ranging from 425 –505 nm.

8. A translucent composition, comprising at least one light filtering component,
said light filtering component specifically transmitting a balance of wavelengths for
15 stimulating a mammalian circadian, photoneural, or neuroendocrine system, said
balance of wavelengths having a peak transmittance ranging from 425 –505 nm.

9. A transparent composition, comprising at least one light filtering component,
said light filtering component specifically blocking a balance of wavelengths for
20 stimulating a mammalian circadian, photoneural, or neuroendocrine system, said
balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

10. A translucent composition, comprising at least one light filtering component,
said light filtering component specifically blocking a balance of wavelengths for
25 stimulating a mammalian circadian, photoneural, or neuroendocrine system, said
balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

11. A method of treating a light responsive disorder in a mammal, comprising
administration of a therapeutically effective amount of light to said mammal, said
30 light being generated by a light system, wherein said light system comprises at least
one light source and at least one transparent material component, said light source
emitting light through said transparent material component, said transparent material
component comprising at least one light filtering component, said light filtering
component specifically transmitting a balance of wavelengths to stimulate a circadian,

BRA01-NP001

PATENT

photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

5 **12.** The method of **Claim 11**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

10 **13.** A method of treating a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system comprises at least one light source and at least one translucent material component, said light source emitting light through said translucent material component, said translucent material
15 component comprising at least one light filtering component, said light filtering component specifically transmitting a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

20 **14.** The method of **Claim 13**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

25 **15.** A method of treating a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system comprises at least one light source and at least one transparent material component, said light source emitting light through said transparent material component, said transparent material
30 component comprising at least one light filtering component, said light filtering component specifically blocking a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –505 nm.

BRA01-NP001

PATENT

16. The method of **Claim 15**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

17. A method of treating a light responsive disorder in a mammal, comprising administration of a therapeutically effective amount of light to said mammal, said light being generated by a light system, wherein said light system comprises at least one light source and at least one translucent material component, said light source emitting light through said translucent material component, said translucent material component comprising at least one light filtering component, said light filtering component specifically blocking a balance of wavelengths to stimulate a circadian, photoneural, or neuroendocrine system of said mammal, said balance of wavelengths having a peak sensitivity ranging from 425 –5055 nm.

18. The method of **Claim 17**, wherein said light responsive disorder is at least one of the group of seasonal affective disorder (SAD), a sleep disorder, circadian disruption, eating disorders, menstrual cycle disorders, non-specific alerting or performance deficits, hormone-sensitive cancers, or cardiovascular disorders.

19. A light meter system for quantifying light which stimulates a mammalian circadian, photoneural, or neuroendocrine system under normal conditions or which provides light therapy, said light meter system comprising at least one light metering device configured to match wavelength sensitivity of mammalian photoreceptors for circadian and neuroendocrine regulation, said wavelength having a peak sensitivity ranging from 425-505 nm.

BRA01-NP001

PATENT

ABSTRACT

The present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm; a light meter system for quantifying light which stimulates or regulates mammalian circadian, photoneural, and neuroendocrine systems. The present invention also relates to translucent and transparent materials, and lamps or other light sources with or without filters capable of stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals. Additionally, the present invention involves treatment of mammals with a wide variety of disorders or deficits, including light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficits, hormone-sensitive cancers, and cardiovascular disorders.

PTO/SB/01A (10-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☒ The attached application, or
☐ Application No. _____, filed on _____,
☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;


I/ we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable; and

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: George Brainard

Signature:  Citizen of: United States

Inventor two: _____

Signature: _____ Citizen of: _____

Inventor three: _____

Signature: _____ Citizen of: _____

Inventor four: _____

Signature: _____ Citizen of: _____

☐ Additional inventors are being named on _____ additional form(s) attached hereto.

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Thomas Jefferson UniversityApplication No./Patent No.: _____ Filed/Issue Date: May 10, 2001Entitled: Photoreceptor System For Melatonin Regulation And Photo TherapyThomas Jefferson University, a University

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

10 May 2001

Date

Alan B. Kelly, Esq.

Typed or printed name

Signature

University Counsel and Senior Officer

Title



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 6772

SERIAL NUMBER 09/853,428	FILING DATE 05/10/2001 RULE	CLASS 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. BRA01-NP002
APPLICANTS George Brainard, Haddonfield, NJ; ** CONTINUING DATA ***** THIS APPLN CLAIMS BENEFIT OF 60/203,308 05/10/2000 AND CLAIMS BENEFIT OF 60/228,493 08/28/2000 ** FOREIGN APPLICATIONS ***** IF REQUIRED, FOREIGN FILING LICENSE GRANTED** SMALL ENTITY ** ** 07/09/2001				
Foreign Priority claimed ☐ yes ☐ no 35 USC 119 (a-d) conditions ☐ yes ☐ no ☐ Met after Allowance Verified and Acknowledged _____ Examiner's Signature _____ Initials _____		STATE OR COUNTRY NJ	SHEETS DRAWING 12	TOTAL CLAIMS 19
			INDEPENDENT CLAIMS 13	
ADDRESS 24358				
TITLE Photoreceptor system for melatonin regulation and phototherapy				
FILING FEE RECEIVED 755	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit	

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

05/15/2001 JBALINAN 00000017 500491 09853428

01 FC:201	355.00 CH
02 FC:202	400.00 CH

Application or Docket Number

PATENT APPLICATION FEE DETERMINATION RECORD

Effective October 1, 2000

CLAIMS AS FILED - PART I

(Column 1)

(Column 2)

TOTAL CLAIMS	19	
FOR	NUMBER FILED	NUMBER EXTRA
TOTAL CHARGEABLE CLAIMS	19 minus 20 = *	
INDEPENDENT CLAIMS	13 minus 3 = *	10
MULTIPLE DEPENDENT CLAIM PRESENT ☐		

SMALL ENTITY TYPE ☐

OR

OTHER THAN SMALL ENTITY

RATE	FEE
BASIC FEE	355.00
X\$ 9=	
X40=	400
+135=	
TOTAL	755

RATE	FEE
BASIC FEE	710.00
X\$18=	
X80=	
+270=	
TOTAL	

* If the difference in column 1 is less than zero, enter "0" in column 2

CLAIMS AS AMENDED - PART II

(Column 1)

(Column 2)

(Column 3)

AMENDMENT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
	Total	*	Minus	**	=
	Independent	*	Minus	***	=
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM ☐				

SMALL ENTITY

OR

OTHER THAN SMALL ENTITY

RATE	ADDITIONAL FEE
X\$ 9=	
X40=	
+135=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$18=	
X80=	
+270=	
TOTAL ADDIT. FEE	

BEST AVAILABLE COPY

(Column 1)

(Column 2)

(Column 3)

AMENDMENT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
	Total	*	Minus	**	=
	Independent	*	Minus	***	=
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM ☐				

RATE	ADDITIONAL FEE
X\$ 9=	
X40=	
+135=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$18=	
X80=	
+270=	
TOTAL ADDIT. FEE	

(Column 1)

(Column 2)

(Column 3)

AMENDMENT C		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
	Total	*	Minus	**	=
	Independent	*	Minus	***	=
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM ☐				

RATE	ADDITIONAL FEE
X\$ 9=	
X40=	
+135=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$18=	
X80=	
+270=	
TOTAL ADDIT. FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20."

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3."

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

CLAIMS ONLY							SERIAL NO. <i>0985 3428</i>	FILING DATE	
							APPLICANT(S)		
CLAIMS									
	AS FILED		AFTER 1st AMENDMENT		AFTER 2nd AMENDMENT			*	
	IND.	DEP.	IND.	DEP.	IND.	DEP.		IND.	DEP.
1							51		
2							52		
3							53		
4							54		
5							55		
6							56		
7							57		
8							58		
9							59		
10							60		
11							61		
12							62		
13							63		
14							64		
15							65		
16							66		
17							67		
18							68		
19							69		
20							70		
21							71		
22							72		
23							73		
24							74		
25							75		
26							76		
27							77		
28							78		
29							79		
30							80		
31							81		
32							82		
33							83		
34							84		
35							85		
36							86		
37							87		
38							88		
39							89		
40							90		
41							91		
42							92		
43							93		
44							94		
45							95		
46							96		
47							97		
48							98		
49							99		
50							100		
TOTAL IND.							TOTAL IND.		
TOTAL DEP.							TOTAL DEP.		
TOTAL CLAIMS							TOTAL CLAIMS		

* MAY BE USED FOR ADDITIONAL CLAIMS OR ADMMENDMENTS

FORM PTO-2022 (1-98)

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

BEST AVAILABLE COPY

DATA SHEET

DOCKET NUMBER:

BRA01-NP002

FILING TITLE:

Photoreceptor System For Melatonin Regulation And
Phototherapy

PRIORITY TO BE CLAIMED:

60/203,308 Filed May 10, 2000

APPLICANT:

THOMAS JEFFERSON UNIVERSITY
1020 Walnut Street
Philadelphia, PA 19107
United States of America

INVENTORS:

George Brainard
813 Mt. Vernon Avenue
Haddonfield, NJ 08033
USA

05-14-01

A

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0851-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. **BRA01-NP002**

First Inventor **BRAINARD, George**

Title **Photoreceptor System For Melatonin Regulation and Phototherapy**

Express Mail Label No. **EJ464028033US**

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages **49**]
(preferred arrangement set forth below)
- Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **12**]5. Oath or Declaration [Total Pages **1**]

- a. ☒ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
- i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).

6. ☒ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ paper
- c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☒ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other: _____

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No.: _____

Prior application information:

Examiner: _____

Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

24358

(insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

Fax

Name (Print Type)

Clifford Kent Weber

Registration No. (Attorney/Agent)

42,215

Signature

Clifford Kent Weber

Date

May 10, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

05/10/01

J1036 U.S. PTO

J1036 U.S. PTO

09/853428

05/10/01

05/10/01
Jc961 U.S. PTO

PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 755.00

Complete if Known

Application Number	
Filing Date	May 10, 2001
First Named Inventor	BRAINARD, George
Examiner Name	
Group Art Unit	
Attorney Docket No.	BRA01-NP002

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 50-0491
Deposit Account Name: Thomas Jefferson University

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☒ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 710	201 355	Utility filing fee	\$355.00
106 320	206 160	Design filing fee	
107 490	207 245	Plant filing fee	
108 710	208 355	Reissue filing fee	
114 150	214 75	Provisional filing fee	

SUBTOTAL (1) (\$ 355.00

2. EXTRA CLAIM FEES

Total Claims: 19
Independent Claims: 13
Multiple Dependent: 6

Extra Claims: 20** = 10 x \$9.00 = \$90.00
- 3** = 10 x \$40.00 = \$400.00

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 80	202 40	Independent claims in excess of 3
104 270	204 135	Multiple dependent claim, if not paid
109 80	209 40	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 400.00

*or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for <i>ex parte</i> reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 390	216 195	Extension for reply within second month	
117 890	217 445	Extension for reply within third month	
118 1,390	218 695	Extension for reply within fourth month	
128 1,890	228 945	Extension for reply within fifth month	
119 310	219 155	Notice of Appeal	
120 310	220 155	Filing a brief in support of an appeal	
121 270	221 135	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,240	241 620	Petition to revive - unintentional	
142 1,240	242 620	Utility issue fee (or reissue)	
143 440	243 220	Design issue fee	
144 600	244 300	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(q)	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 710	246 355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 710	249 355	For each additional invention to be examined (37 CFR § 1.129(b))	
179 710	279 355	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0.00

SUBMITTED BY

Name (Print/Type) Clifford Kent Weber

Signature

Registration No. (Attorney/Agent)

42,215

Complete (if applicable)

Telephone (215) 503-0757

Date

May 10, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.: BRA01-NP002

TITLE: Photoreceptor System For Melatonin Regulation And Phototherapy

INVENTOR(S): BRAINARD, George

"Express Mail" Label No. EJ464028033US

Date of Deposit – May 10, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

By Clifford Kent Weber

Typed Name: Clifford Kent Weber

Box Patent Application

Commissioner of Patents & Trademarks
Washington, DC 20231

0
1
2
3
4
5
6
7
8
9
10
11
12



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

Paper No. 9

COPY MAILED

FEB 04 2003

OFFICE OF PETITIONS

In re Application of
George Brainard
Application No. 09/853,428
Filed: May 10, 2001
Attorney Docket No. BRA01-NP002

:
:
: DECISION ON PETITION
:
:

This is a decision on the petition filed January 21, 2003, to revive the above-identified application. Petitioner requests revival based upon an unintentional delay in responding to the Office action under 37 CFR 1.137(a).

The petition under 37 CFR 1.137(a) is dismissed.

Any further petition to revive the above-identified application must be submitted within TWO (2) MONTHS from the mail date of this decision. Extensions of time under 37 CFR 1.136(a) are permitted. The reconsideration request should include a cover letter entitled "Renewed Petition under 37 CFR 1.137." This is **not** final agency action within the meaning of 5 U.S.C. § 704.

The above-identified application became abandoned for failure to timely and properly reply to the non-final Office action, mailed June 6, 2002. The Office action set a three (3) month period for reply. No extensions of time having been obtained under 37 CFR 1.136(a), this application became abandoned on September 7, 2002. A Notice of Abandonment was mailed on December 10, 2002.

Petitioner asserts that the delay was unavoidable because Petitioner has not received the June 6, 2002, Office action.

A grantable petition to revive an abandoned application under 37 CFR 1.137(a) must be accompanied by (1) a proposed response to continue prosecution of the abandoned application, or filing of a continuation application, unless either has been previously filed; (2) the petition fee required by 37 CFR 1.17(l); (3) an adequate verified showing of the cause of unintentional delay; and (4) a terminal disclaimer and fee. This petition lacks items (1) and (3) above.

As to item (1), Petitioner has not provided a response to the Office action.

As to item (3), an allegation that an Office action was not received may be considered as a petition for the withdrawal of the holding of abandonment. If the allegation is adequately supported, the petition may be granted and a new Office action mailed. The showing required to establish nonreceipt of an Office communication must include:

1. A statement from the practitioner stating that the Office communication was not received by the practitioner and attesting to the fact that a search of the file jacket and docket records indicates that the Office communication was not received.

Application No. 09/853,428

Page 2

2. A copy of the docket record where the non-received Office communication would have been entered had it been received and docketed must be attached to and referenced in practitioner's statement.¹

A review of the record indicates no irregularity in the mailing of the June 6, 2002 Office action, and in the absence of any irregularity there is a strong presumption that the communication was properly mailed to the applicant at the correspondence address of record. This presumption may be overcome by a showing that the aforementioned communication was not in fact received at the correspondence address of record.

Petitioner's deposit account has been charged an additional \$30.00 as authorized in the instant petition which represents the balance due for a petition to revive an unintentionally abandoned application.

Further correspondence with respect to this matter should be addressed as follows:

By mail: Commissioner for Patents
Box DAC
Washington, D.C. 20231

By facsimile: (703) 308-6916
Attn: Office of Petitions

By hand: Office of Petitions
2201 South Clark Place
Crystal Plaza 4, Suite 3C23
Arlington, VA 22202

Telephone inquiries concerning this decision should be directed to the undersigned at (703) 305-0014.


Derek L. Woods
Petitions Attorney
Office of Petitions

Enclosure: Office Action of June 6, 2002.

¹ See notice entitled "Withdrawing the Holding of Abandonment When Office Actions Are Not Received," 1156 O.G. 53 (November 16, 1993).

L Number	Hits	Search Text	DB	Tim stamp
1	3	((("5447527") r ("5855595") or ("5170035")).PN.	USPAT; US-PGPUB	2002/05/30 15:20
2	1	("5235178").PN.	USPAT; US-PGPUB	2002/05/30 15:19
3	3	"5824024"	USPAT; US-PGPUB	2002/05/30 15:21
4	1121	(circadian photoneural neuroendocrine) and light	USPAT; US-PGPUB	2002/05/30 15:35
5	73	((circadian photoneural neuroendocrine) and light) and ("400" "425" "500" "505" "550") adj nm	USPAT; US-PGPUB	2002/05/30 15:23
7	1	((((circadian photoneural neuroendocrine) and light) and ("400" "425" "500" "505" "525" "550") adj nm) and (light adj filter\$3)	USPAT; US-PGPUB	2002/05/30 15:26
8	581	circadian and light	USPAT; US-PGPUB	2002/05/30 15:36
6	77	((circadian photoneural neuroendocrine) and light) and ("400" "425" "500" "505" "525" "550") adj nm	USPAT; US-PGPUB	2002/05/30 15:37

L Number	Hits	Search Text	DB	Time stamp
1	1	("5083858").PN.	USPAT; US-PGPUB	2002/05/31 09:38
2	5	5083858.URPN.	USPAT	2002/05/31 08:59
3	2	("3826751" "4783361").PN.	USPAT	2002/05/31 09:03
4	95	melatonin with (reduction reducing suppress\$3)	USPAT; US-PGPUB	2002/05/31 09:39
5	79	{melatonin with (reduction reducing suppress\$3)) and light	USPAT; US-PGPUB	2002/05/31 09:39
6	47	(melatonin with (reduction reducing suppress\$3)) same light	USPAT; US-PGPUB	2002/05/31 09:39
7	23	((melatonin with (reduction reducing suppress\$3)) same light) and filter	USPAT; US-PGPUB	2002/05/31 09:40
8	7	((((melatonin with (reduction reducing suppress\$3)) same light) and filter) and wavelength	USPAT; US-PGPUB	2002/05/31 09:40
9	12	("5163426" "5167228" "5176133" "5304212" "5447527" "5447528" "5485737" "5503637" "5545192" "5562719" "5824024" "5919217").PN.	USPAT	2002/05/31 09:45
10	1		USPAT	2002/05/31 09:54
11	5	5447527.URPN.	USPAT	2002/05/31 09:54
12	4	("5304212" "5447527" "5447528" "5562719").PN.	USPAT	2002/05/31 09:56



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/853,428	05/10/2001	George Brainard	BRA01-NP002	6772

24358 7590 06/06/2002

THOMAS JEFFERSON UNIVERSITY
 INTELLECTUAL PROPERTY DIVISION
 1020 WALNUT STREET
 SUITE 620
 PHILADELPHIA, PA 19107

EXAMINER

GIBSON, ROY DEAN

ART UNIT

PAPER NUMBER

3739

DATE MAILED: 06/06/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

m

Office Action Summary

Application No.

09/853,428

Applicant(s)

BRAINARD, GEORGE

Examiner

Roy D. Gibson

Art Unit

3739

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 May 2001.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-19 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

Application/Control Number: 09/853,428
Art Unit: 3739

Page 2

DETAILED ACTION

Claim Rejections - 35 USC § 112

Claims 3-4 and 15-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It is unclear how the method of treating a light responsive disorder can be claimed both as an the exposure of the light and independently as a blocking of the same light. The specification teaches a sequence of both.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 2, 5 and 11-14 are rejected under 35 U.S.C. 102(b) as being anticipated by Waldman (5,447,527). Waldman discloses a method of treating a light responsive disorder (SAD) comprising:

administering a therapeutically effective amount of light to the patient, the light being generated by a light system (lamp # 4 with filter # 7) the filter transmitting in the range 490-520 nm, which overlaps the range of 425-505 nm (col. 1, lines 11-22, col. 1,

Application/Control Number: 09/853,428
Art Unit: 3739

Page 3

line 64-col. 2, line 19, col. 3, lines 1-23 and col. 4, line 33-41). Note that the filter could be transparent or translucent depending upon the thickness of the coating material(s).

Claims 6, 9 and 10 are rejected under 35 U.S.C. 102(b) as being anticipated by Fujishima et al. (5,855,595) who disclose a tumor treatment apparatus with a light source and a filter which blocks the wavelength range of 400-700 nm (Figures 1 and 4 and col. 1, lines 21-46).

Claims 7 and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Girerd (5,083,858). Girerd discloses a transparent or translucent composition (depending upon the thickness of the layers) comprising at least one filtering component which transmits a balance of wavelengths having a peak transmittance ranging from 425-505 nm (peak @ 493 nm and col. 10, lines 31-65, col. 11, line 36-col. 12, line 34 or col. 12, line 55-col. 13, line 33).

Claim 19 is rejected under 35 U.S.C. 102(b) as being anticipated by Hegyi (5,235,178). Hegyi discloses a light sensor with diffuser whereby the electrical output signal is representative of a response characteristic applied to the input light which corresponds to that of a human eye or is equivalent to a light meter system comprising a light metering device configured to match wavelength sensitivity of the human eye (col. 4, line 1-col. 5, line 20).

Application/Control Number: 09/853,428

Page 4

Art Unit: 3739

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1, 2 and 5 are rejected under 35 U.S.C. 102(e) as being anticipated by Goldman (5,923,398). Goldman discloses a method of treating a light responsive disorder (circadian disruption) comprising:

administering a therapeutically effective amount of light to the patient, the light being generated by a light system (LEDs emitting in the range of 500-560 nm, which overlaps the range of 425-505 nm) to stimulate a circadian system (col. 1, lines 20-45, col. 1, line 65-col. 2, lines 9, and col. 5, lines 18-30).

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Dial (5,824,024) discloses an illumination device for treating light deficiency and mood disorders that reads on claims 1 and 2; Cole (4,858,6090 discloses a bright light mask that reads on claims 1 and 2; Czeisler et al. (5,545,192) disclose use of light to modify the circadian phase; Lopez-Claros (5,562,719) discloses a

Application/Control Number: 09/853,428

Page 5

Art Unit: 3739

light therapy method and apparatus for treating SAD; and Gerdt (6,235,046) discloses a passive photonic eye delivers system for chronotherapy.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roy D. Gibson whose telephone number is 703-308-3520. The examiner can normally be reached on M-F, 7:30 am-4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda Dvorak can be reached on 703-308-0994. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9302 for regular communications and 703-872-9303 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0873.

May 31, 2002


Roy Gibson
Primary Examiner
Art Unit 3739

08/18/02 FRI 14:11 FAX 617 345 1300

ON PEABODY

DCI
8-21-02
#31 Chng
at
Address
PATENT

Practitioner's Docket No. 252-52961 (formerly BRA01-NP002)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Brainard

Application No.: 09/853,428

Filed: May 10, 2001

For: PHOTORECEPTOR SYSTEM FOR MELATONIN REGULATION AND PHOTOTHERAPY

Group No.: 1614

Examiner: Not yet assigned

Assistant Commissioner for Patents

Washington, D.C. 20231


CHANGE OF ATTORNEY'S ADDRESS IN APPLICATION

Please send all correspondence for this application as follows:

David S. Resnick
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110

Please direct telephone calls to: (617) 345-6057

The Power of Attorney appointing the aforementioned as an agent of the Applicant is forthcoming.


SIGNATURE OF PRACTITIONER

Reg. No. 34,235
Under 37 CFR § 10.9(b)
Tel. No.: (617) 345-6057

David S. Resnick
Leena H. Karttunen
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


0 deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

8/16/02

FACSIMILE

Y transmitted by facsimile to the Patent and Trademark Office.


Signature

Zinna L. Mang

(Change of Attorney's Address in Application, page 1 of 1)


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Leena Karttunen is hereby given limited recognition under 37 CFR § 10.9(b), as an employee of the law firm of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is a client of the law firm of Nixon Peabody LLP, and a registered practitioner, who is a member of the law firm of Nixon Peabody LLP, is the practitioner of record in the applications. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena Karttunen ceases to lawfully reside in the United States, (ii) Leena Karttunen's employment with the law firm of Nixon Peabody LLP, ceases or is terminated, or (iii) Leena Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such limited recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: December 4, 2002


Harry I. Moatz
Director of Enrollment and Discipline